<SEC-DOCUMENT>0001723464-26-000028.txt : 20260514
<SEC-HEADER>0001723464-26-000028.hdr.sgml : 20260514
<ACCEPTANCE-DATETIME>20260514130650
ACCESSION NUMBER:		0001723464-26-000028
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260514
DATE AS OF CHANGE:		20260514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOHARVEST SCIENCES INC.
		CENTRAL INDEX KEY:			0001723464
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42389
		FILM NUMBER:		26977411

	BUSINESS ADDRESS:	
		STREET 1:		1140 - 625 HOWE STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 2T6
		BUSINESS PHONE:		6046221186

	MAIL ADDRESS:	
		STREET 1:		1140 - 625 HOWE STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 2T6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CANNA-V-CELL SCIENCES INC.
		DATE OF NAME CHANGE:	20191008

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Midnight Star Ventures Corp.
		DATE OF NAME CHANGE:	20171121
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bhsc_6k.htm
<DESCRIPTION>REPORT
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2026 [PPXC4Y912124VAJXLJL1]. www.edgarsuite.com -->
<HEAD>
<TITLE>Report</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:467.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>UNITED STATES</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>WASHINGTON, DC 20549</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:14pt Times New Roman;margin:0'><B>FORM 6-K</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>For the month of <B>May 2026</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>Commission file number: <B>001-42389</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:16pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Exact name of Registrant as specified in its charter)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Not applicable</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Translation of Registrant&#8217;s name into English)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>(Address of principal executive offices)</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT> Form 20-F&nbsp;<FONT style='font-family:Segoe UI Symbol'>&#9746;</FONT> Form 40-F</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT style='font-family:Segoe UI Symbol'>&#9744;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:468pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><A name=_PART_III /><A name=_ITEM_19._EXHIBITS /><B>SUBMITTED HEREWITH</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Exhibits:</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:49.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><B>Exhibit</B></P>
</TD><TD valign=bottom style=width:418.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><B>Description</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:49.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#215E99;border-bottom:1px solid #215E99'><A href=bhsc_ex991.htm style=text-decoration:none>99.1</A></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:418.5pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:10pt Times New Roman;margin:0'>Unaudited Interim Condensed Consolidated Financial Statements for the three months ended March 31, 2026</P>
</TD></TR>
<TR><TD valign=top style=width:49.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#215E99;border-bottom:1px solid #215E99'><A href=bhsc_ex992.htm style=text-decoration:none>99.2</A></FONT></P>
</TD><TD valign=top style=width:418.5pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:10pt Times New Roman;margin:0'>Management&#8217;s Discussion and Analysis for the three months ended March 31, 2026</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:49.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#215E99;border-bottom:1px solid #215E99'><A href=bhsc_ex993.htm style=text-decoration:none>99.3</A></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:418.5pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:10pt Times New Roman;margin:0'>Form 52-109F2 - Certification of Interim Filings &#8211;&nbsp;Full Certificate - CEO</P>
</TD></TR>
<TR><TD valign=top style=width:49.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#215E99;border-bottom:1px solid #215E99'><A href=bhsc_ex994.htm style=text-decoration:none>99.4</A></FONT></P>
</TD><TD valign=top style=width:418.5pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:10pt Times New Roman;margin:0'>Form 52-109F2 - Certification of Interim Filings &#8211;&nbsp;Full Certificate - CFO</P>
</TD></TR>
</TABLE>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><A name=_SIGNATURES /><A name=_Toc169189235 /><A name=_Toc172699253 /><B>SIGNATURES</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>(Registrant)</P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>Date: May 14, 2026</P>
</TD><TD valign=top style='width:233.75pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><I>/s/ David Ryan</I></P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:233.75pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Name: David Ryan</P>
</TD></TR>
<TR><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:233.75pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:10pt Times New Roman;margin:0'>Title: Vice-President, Investor Relations &amp; Secretary</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bhsc_ex991.htm
<DESCRIPTION>UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2026 [PPXC4Y912124VAJXLJL1]. www.edgarsuite.com -->
<HEAD>
<TITLE>Unaudited Interim Condensed Consolidated Financial Statements</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:451.35pt><P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><IMG src=bhscex991_1.jpg width=339 height=70 alt='Picture 897728671' title='Picture 897728671'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:24pt Times New Roman;margin-top:0pt;margin-bottom:10pt;color:#000000'><B>BioHarvest Sciences Inc.</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>For the Three Months Ended March 31, 2026</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>Expressed in U.S. dollars in thousands</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:56.7pt;width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:24pt Times New Roman;margin-top:0pt;margin-bottom:10pt;color:#000000'><B>BioHarvest Sciences Inc.</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>For the Three Months Ended March 31, 2026</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>Expressed in U.S. dollars in thousands</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>TABLE OF CONTENTS</B></FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:453.75pt><P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:45.35pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Page</B></P>
</TD></TR>
<TR><TD valign=top style=width:453.75pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>FINANCIAL STATEMENTS:</B></P>
</TD><TD valign=top style='width:45.35pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:453.75pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=#bs style=text-decoration:none>Unaudited Interim Condensed Consolidated Statements of Financial Position</A></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:45.35pt><P align=center style='font:10pt Times New Roman;margin:0'>3</P>
</TD></TR>
<TR><TD valign=top style=width:453.75pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=#sop style=text-decoration:none>Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss</A></FONT></P>
</TD><TD valign=top style=width:45.35pt><P align=center style='font:10pt Times New Roman;margin:0'>4</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:453.75pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=#sse style=text-decoration:none>Unaudited Interim Condensed Consolidated </A><A href=#sse style=text-decoration:none>Statements of Changes in Shareholders</A><A href=#sse style=text-decoration:none>&#8217;</A><A href=#sse style=text-decoration:none> Equity</A></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:45.35pt><P align=center style='font:10pt Times New Roman;margin:0'>5</P>
</TD></TR>
<TR><TD valign=top style=width:453.75pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=#cfs style=text-decoration:none>Unaudited Interim Condensed Consolidated Statements of Cash Flows</A></FONT></P>
</TD><TD valign=top style=width:45.35pt><P align=center style='font:10pt Times New Roman;margin:0'>6</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:453.75pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=#notes style=text-decoration:none>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</A></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:45.35pt><P align=center style='font:10pt Times New Roman;margin:0'>7-21</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:481.95pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B></FONT><FONT style=font-size:16pt> </FONT><FONT style=font-size:14pt><B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Unaudited Interim Condensed Consolidated Statements of Financial Position</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>USD dollars in thousands</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><TABLE style=border-collapse:collapse;width:100%><TR style=height:3.7pt><TD valign=middle style=width:233.9pt rowspan='2'><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:35.45pt rowspan='2'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt'><B>Note</B></P>
</TD><TD valign=bottom style=width:106.3pt><P align=center style='font:10pt Times New Roman;margin:0;margin-right:2.85pt'><B>As of March 31,</B></P>
</TD><TD valign=bottom style=width:106.3pt><P align=center style='font:10pt Times New Roman;margin:0;margin-right:2.85pt'><B>As of December 31,</B></P>
</TD></TR>
<TR style=height:3.7pt><TD valign=bottom style='width:106.3pt;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>2026</B></P>
</TD><TD valign=bottom style='width:106.3pt;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Assets</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:106.3pt;border-top:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:17pt;margin-right:17pt'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:106.3pt;border-top:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:17pt;margin-right:17pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Current assets</B></P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:17pt;margin-right:17pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:17pt;margin-right:17pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Cash and cash equivalents</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>$ 19,167</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>$ 23,025</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Bank deposits</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>1,001</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Trade accounts receivable</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>2,120</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>1,981</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Other accounts receivable</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>1,061</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>935</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Inventory</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>4,971</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>4,559</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total current assets</B></P>
</TD><TD valign=middle style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>28,320</B></P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>30,500</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Non-current assets</B></P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Restricted cash</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>436</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>433</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Property, plant and equipment, net</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>8,550</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>8,326</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Right-of-use assets, net</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>8,252</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>8,406</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total non-current assets</B></P>
</TD><TD valign=middle style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>17,238</B></P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>17,165</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total assets</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>$ 45,558</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>$ 47,665</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-top:1.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:35.45pt;border-top:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Liabilities</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:7.1pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Current liabilities</B></P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Trade accounts payable</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>$ 2,682</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>$ 2,627</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Other accounts payable</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>2,631</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>2,173</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt'>Deferred revenue</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>474</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>492</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt'>Lease liabilities</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>1,271</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>1,405</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt'>Loans</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt'>3</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>1,732</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>149</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt'>Liability for Agricultural Research Organization</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>6</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>457</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>452</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Accrued liabilities</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>331</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>386</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total current liabilities</B></P>
</TD><TD valign=middle style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>9,578</B></P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>7,684</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Non-current liabilities</B></P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Lease liabilities</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>10,251</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>10,130</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Loans</P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>3</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt'><B>786</B></P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt'>2,420</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Liability for <FONT style=font-family:Calibri>Agricultural Research Organization</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>6</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>1,920</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>1,983</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total non-current liabilities</B></P>
</TD><TD valign=middle style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>12,957</B></P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>14,533</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Shareholders&#8217; equity</B></P>
</TD><TD valign=middle style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:0.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.9pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Share capital and contributed surplus</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:35.45pt><P align=center style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:0.15pt;color:#000000'>4</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>133,217</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:106.3pt><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>133,001</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Accumulated deficit</P>
</TD><TD valign=middle style='width:35.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(110,194)</B></P>
</TD><TD valign=middle style='width:106.3pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;text-indent:-1.4pt;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(107,553)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total Shareholders&#8217; equity</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:0.5pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>23,023</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:0.5pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>25,448</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.9pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0;color:#000000'><B>Total liabilities and shareholders&#8217; equity</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:35.45pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>$ 45,558</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:106.3pt;border-top:1pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>$ 47,665</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:90%><TR><TD valign=top style='width:124.7pt;border-bottom:0.75pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>May 14, 2026</P>
</TD><TD valign=top style=width:14.15pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt'>&nbsp;</P>
</TD><TD valign=top style='width:124.7pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt'>&#8216;Zaki Rakib&#8217;</P>
</TD><TD valign=top style='width:124.7pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt'>&#8216;Ilan Sobel&#8217;</P>
</TD></TR>
<TR style=height:23.1pt><TD valign=top style=width:124.7pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt'>Date of approval of the financial statements</P>
</TD><TD valign=top style=width:14.15pt><P align=center style='font:10pt Times New Roman;margin:0;margin-left:2.85pt'>&nbsp;</P>
</TD><TD valign=top style='width:124.7pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Chief Executive Officer and Chairman of the Board</P>
</TD><TD valign=top style='width:124.7pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Director</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0;color:#000000'><I>The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>3</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B></FONT><FONT style=font-size:16pt> </FONT><FONT style=font-size:14pt><B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>USD in thousands, except per share data</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><TABLE style=border-collapse:collapse;width:100%><TR style=height:2.2pt><TD valign=bottom style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt rowspan='2'><P align=justify style='font:11pt Times New Roman;margin-top:7.2pt;margin-bottom:0pt;color:#000000'>&nbsp;</P>
</TD><TD colspan=2 valign=bottom style='width:194.55pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>Three Months Ended March 31,</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>2026</B></P>
</TD><TD valign=top style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'><A name=sop />Revenues</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>$ 8,507</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>$ 7,860</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Cost of revenues</P>
</TD><TD valign=bottom style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(3,470)</B></P>
</TD><TD valign=bottom style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(3,265)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Gross profit</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>5,037</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>4,595</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;color:#000000'><B>Operating expenses</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Research and development</P>
</TD><TD valign=bottom style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(1,394)</B></P>
</TD><TD valign=bottom style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(1,245)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Sales and marketing</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(4,126)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(3,681)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>General and administrative</P>
</TD><TD valign=bottom style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(1,351)</B></P>
</TD><TD valign=bottom style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(1,388)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Total operating expenses</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(6,871)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(6,314)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'><B>Operating loss</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(1,834)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(1,719)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Finance income</P>
</TD><TD valign=bottom style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>114</B></P>
</TD><TD valign=bottom style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Finance expenses</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(875)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(581)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Net loss before tax</B></P>
</TD><TD valign=bottom style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(2,595)</B></P>
</TD><TD valign=bottom style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(2,300)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Taxes on income</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(46)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>(38)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Net loss and comprehensive loss</B></P>
</TD><TD valign=bottom style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'><B>(2,641)</B></P>
</TD><TD valign=bottom style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>$ (2,338)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:287.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:97.25pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>Basic and Diluted loss per share</P>
</TD><TD valign=bottom style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>(0.11)</P>
</TD><TD valign=bottom style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>(0.13)</P>
</TD></TR>
<TR style=height:5.4pt><TD valign=middle bgcolor=#DBE5F1 style=width:287.4pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>Weighted Average Number of Shares Outstanding</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>22,667,365</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:97.25pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'>17,327,716</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0;color:#000000'><I>The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>4</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:72pt;width:698pt><TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:662pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:662pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity</B></P>
</TD></TR>
<TR><TD valign=top style='width:662pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>USD in thousands, except per share data</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><TABLE style=border-collapse:collapse;width:100%><TR style=height:24.25pt><TD valign=bottom style='width:280.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Number of shares</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Share Capital and contributed surplus</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Accumulated deficit</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Total equity</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:280.4pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><A name=sse /><B>Balance, December 31, 2024</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>17,327,716</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ 97,748</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ (96,418)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ 1,330</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:280.4pt><P style='font:11pt Times New Roman;margin:0'>Share based compensation</P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>-</P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>132</P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>-</P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>132</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:280.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Comprehensive loss for the period</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>-</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>-</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>(2,338)</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'>(2,338)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:280.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance, March 31, 2025</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>17,327,716</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ 97,880</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ (98,756)</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ 876</B></P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR style=height:24.25pt><TD valign=bottom style='width:280.4pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Number of shares</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Share Capital and contributed surplus</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Accumulated deficit</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Total equity</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:280.4pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance, December 31, 2025</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>22,666,842</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ 133,001</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ (107,553)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:1pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>$ 25,448</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:280.4pt><P style='font:11pt Times New Roman;margin:0'>Share based compensation</P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>-</B></P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>216</B></P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>-</B></P>
</TD><TD valign=bottom style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>216</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:280.4pt><P style='font:11pt Times New Roman;margin:0'>Issuance of shares upon vesting of RSUs</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>1,000</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>-</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>-</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:104.4pt><P align=right style='font:11pt Times New Roman;margin:0;margin-right:5.65pt'><B>-</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:280.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Comprehensive loss for the period</P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>-</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>-</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>(2,641)</B></P>
</TD><TD valign=bottom style='width:104.4pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>(2,641)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:280.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance, March 31, 2026</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>22,667,842</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>$ 133,217</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>(110,194)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:104.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:5.65pt'><B>$ 23,023</B></P>
</TD></TR>
</TABLE>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P style='font:8pt Times New Roman;margin:0;margin-left:-9pt'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0;text-indent:-42.55pt;color:#000000'><I>The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>5</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:56.7pt;width:481.95pt><TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc. and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Unaudited Interim Condensed Consolidated Statements of Cash Flows</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>USD in thousands</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><TABLE style=border-collapse:collapse;width:100%><TR style=height:9.55pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=2 valign=middle style='width:141.75pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'><B>Three Months Ended</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'><B>March 31,</B></P>
</TD></TR>
<TR style=height:9.55pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:70.9pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2025</B></P>
</TD><TD valign=bottom style='width:70.85pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2024</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0'><A name=cfs /><B>Cash flows from operating activities:</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:70.9pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:70.85pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Net loss</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>$ (2,641)</B></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>$ (2,338)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0'><B>Adjustments to reconcile net loss to net cash used in operating activities:</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:13.85pt;color:#FF0000'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:13.85pt;color:#FF0000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Depreciation and Amortization</P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><FONT style=font-family:Calibri><B>428</B></FONT></P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>399</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Interest over Liability for Agricultural Research Organization</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>57</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>70</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Finance expense (income), net</P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><B>552</B></P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>299</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Share based compensation</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>216</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>132</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0'><B>Changes in assets and liabilities items:</B></P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>&nbsp;</P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Change in Trade accounts receivable</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><FONT style=font-family:Calibri><B>(139)</B></FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>(360)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Change in Other accounts receivable</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><FONT style=font-family:Calibri><B>(135)</B></FONT></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>(59)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Change in Inventory</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><B>(412)</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>(357)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Changes in Trade accounts payable, Other accounts payable and Accrued liabilities</P>
</TD><TD valign=top style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><FONT style=font-family:Calibri><B>712</B></FONT></P>
</TD><TD valign=top style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>563</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:340.2pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Changes in deferred revenue</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:70.9pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><B>(17)</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:70.85pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>224</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:340.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Net cash used in operating activities</B></P>
</TD><TD valign=middle style='width:70.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(1,379)</B></P>
</TD><TD valign=middle style='width:70.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(1,427)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style='width:340.2pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.9pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;color:#000000'><B>Cash flow from investing activities:</B></P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:13.85pt'>&nbsp;</P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:13.85pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Purchase of property and equipment</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(593)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>(684)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Deposit of restricted cash for bank guarantee, net of drawing</P>
</TD><TD valign=middle style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><B>-</B></P>
</TD><TD valign=middle style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>4</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:340.2pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;color:#000000'>Deposits placed in short-term bank deposits</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.9pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><B>(1,000)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:340.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Net cash used in investing activities</B></P>
</TD><TD valign=middle style='width:70.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(1,593)</B></P>
</TD><TD valign=middle style='width:70.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(680)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style='width:340.2pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.9pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0'><B>Cash flow from financing activities</B></P>
</TD><TD valign=middle style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:13.85pt'>&nbsp;</P>
</TD><TD valign=middle style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:13.85pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Repayments of lease liabilities</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(507)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>(221)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Repayments of loans (principal and interest)</P>
</TD><TD valign=middle style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(198)</B></P>
</TD><TD valign=middle style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Repayment of royalties&#8217; liability to the Agricultural Research Organization</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(105)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Proceeds from loans</P>
</TD><TD valign=middle style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>-</B></P>
</TD><TD valign=middle style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>3,343</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:340.2pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Payments of finder fees</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.9pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(30)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>-</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:340.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Net cash (used in) provided by financing activities</B></P>
</TD><TD valign=middle style='width:70.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(840)</B></P>
</TD><TD valign=middle style='width:70.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>3,122</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style='width:340.2pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-8.5pt;margin-left:11.35pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.9pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Exchange rate differences on cash and cash equivalents</P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'><FONT style=font-family:Calibri><B>(46)</B></FONT></P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt'>(4)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Increase (decrease) in cash and cash equivalents</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>(3,812)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>1,015</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:340.2pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Cash and cash equivalents at the beginning of the period</P>
</TD><TD valign=middle style='width:70.9pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>23,025</B></P>
</TD><TD valign=middle style='width:70.85pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>2,390</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom bgcolor=#DBE5F1 style='width:340.2pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Cash and cash equivalents at the end of the period</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.9pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>$ 19,167</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>$ 3,401</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:340.2pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:70.9pt;border-top:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle style='width:70.85pt;border-top:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;color:#000000'><B>Supplemental disclosure of significant non-cash transactions:</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Recognition of right-of-use assets and lease liabilities</P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>127</B></P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;color:#000000'><B>Supplemental disclosure of cash flow information:</B></P>
</TD><TD valign=bottom style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD><TD valign=bottom style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:340.2pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Taxes paid</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.9pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'><B>-</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style=width:70.85pt><P align=right style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:7.15pt;color:#000000'>-</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:9pt Times New Roman;margin:0'><I>The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>6</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin-top:0pt;margin-bottom:6pt'><B>NOTE 1 - GENERAL:</B></P>
<P style='font:11pt Times New Roman;margin:0'><A name=notes /><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>A.</B></KBD><KBD style=margin-left:37pt></KBD><B>Description of the Company and its operations:</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>BioHarvest Sciences Inc. (the &#8220;Company&#8221; or &#8220;BioHarvest Sciences&#8221;), together with its wholly owned subsidiaries, was incorporated under the Business Corporations Act of British Columbia on April 19, 2013. The Company fully owns BioHarvest Ltd. (&#8220;BioHarvest&#8221;), a company incorporated in Israel and commenced its activity on July 2007, and Superfood Nutraceuticals Inc. (&#8220;Superfood&#8221;) a wholly owned subsidiary incorporated in Delaware, USA in July 2014.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In July 2014, BioHarvest incorporated a Delaware based wholly owned subsidiary, BioHarvest Inc (&#8220;BioHarvest Inc&#8221;).</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company is publicly listed and traded on the Nasdaq Stock Market under the symbol BHST and traded on the Frankfurt Stock Exchange, Munich Stock Exchange, Stuttgart Stock Exchange and Dusseldorf Stock Exchange under the symbol 8MV0.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In February 2025, the Company completed a voluntary delisting process of its common shares from the Canadian Securities Exchange and continue to be listed on the Nasdaq Stock Market.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The registered address of the Company is 1140-625 Howe St., Vancouver, BC V6C 2T6, Canada.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><I>Description of Business</I></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company is a biotechnology company that has developed the Botanical Synthesis Platform Technology, which enables the Company to grow, on an industrial scale, the active and beneficial ingredients in certain fruits and plants without the need to grow the plant itself. The Botanical Synthesis Platform Technology is the only non-genetically modified organism platform that can produce plant cells with significantly higher concentrations of active ingredients (as compared to those that are produced naturally), as well as extremely high levels of solubility and bio-availability. The Botanical Synthesis Platform Technology is economical, ensures consistency and avoids the negative environmental impacts associated with traditional agriculture by providing consistent product production, a year-round production cycle and products that are devoid of sugar, calories and contaminants, such as pesticides, heavy metals and residues.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company is currently focused on utilizing the Botanical Synthesis Platform Technology to develop the next generation of science-based and clinically proven therapeutic solutions through two business units:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>1.</KBD><B>The Products Business Unit</B> - Marketing and sales of science-based health and wellness nutraceutical solutions, sold as dietary supplements, functional food and beverages (capsules, powders, chews, coffee, teas and powder electrolyte beverages). The Products Business Unit sources its red grape cell powder from the CDMO Services Business Unit, it then uses other third-party manufacturers and contractors to encapsulate, integrate, package and ship the finished product for the direct sale to end consumers.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:72pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>2.</KBD><B>The CDMO Services Business Unit - </B>A Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;) providing end-to-end development and manufacturing services for plant-based active molecules to pharmaceuticals, cosmeceuticals, nutraceuticals and nutrition customers. The CDMO serves both the Company&#8217;s Products Business Unit (as its exclusive manufacturer of VINIA&#174; red grape cell powder) and external customers from the pharmaceutical, cosmeceutical, nutraceutical and nutrition industries.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.8pt;margin-left:36pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>For further details regarding the Company&#8217;s operating segments and management&#8217;s new approach as of January 1, 2026, please refer to Note 8.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>7</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><FONT style=font-size:12pt><B>NOTE 1 - GENERAL </B><B>(Continued)</B><B>:</B></FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>B.</B></KBD><KBD style=margin-left:18pt></KBD><B>Going concern:</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The unaudited interim condensed consolidated financial statements have been prepared on a going concern basis in accordance with International Financial Reporting Standards. Management has evaluated the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date these unaudited interim condensed consolidated financial statements are issued.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company has a history of operating losses and has not yet achieved sustained cash-flow profitability. For the three months ended March 31, 2026, the Company generated revenues of $8,507 and incurred a net operating loss. As of March 31, 2026, the Company had cash and cash equivalents of $19,167. These conditions, together with the need for continued investment in operations and the uncertainty regarding the timing and availability of additional financing, represent factors that raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company may require additional capital to fund its long-term growth strategy and planned capital investments. &nbsp;If required, the Company intends to raise such capital through one or more of the following: the issuance of equity or equity-linked securities, debt financing, strategic collaborations, licensing arrangements or other financing transactions. The Company is listed on the Nasdaq Capital Market and has previously demonstrated access to the capital markets; however, there can be no assurance that additional financing will be available on acceptable terms, or at all.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Based on management&#8217;s assessment, the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, despite the factors noted above, the going concern basis of preparation remains appropriate, and these unaudited interim condensed consolidated financial statements do not include any adjustments that might result from the outcome of uncertainties related to the going concern assessment.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The unaudited interim condensed consolidated financial statements of the Company were authorized for issue by the Board of Directors on May 14, 2026.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>C.</B></KBD><KBD style=margin-left:18pt></KBD><B>War in Israel:</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company&#8217;s principal place of business, operations and its facilities, where most of its employees are employed, are located in Rehovot and Yavne, Israel. In addition, the majority of the Company&#8217;s key employees and senior management are Israeli citizens.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On October 7, 2023, Hamas militants infiltrated Israel&#8217;s southern border from the Gaza Strip and carried out attacks against civilian and military targets in Israel. Following these events, the Government of Israel declared war against Hamas and the Israel Defense Forces initiated a large-scale mobilization of military reservists. Hostilities between Israel and Hamas continued through 2023, 2024 and 2025. On October 9, 2025, the Israeli Cabinet approved a ceasefire and hostage exchange agreement between Israel and Hamas that was brokered by the United States and took effect on October 10, 2025.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>During this period, hostilities also escalated along Israel&#8217;s northern border involving Hezbollah forces operating from Lebanon. On November 27, 2024, Israel and Lebanon agreed to a ceasefire arrangement that remained in effect until February 18, 2025.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In June 2025, tensions between Israel and Iran escalated significantly and resulted in military operations between the two countries. On June 24, 2025, Israel and Iran agreed to an immediate ceasefire.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>8</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 1- GENERAL (CONTINUED):</B></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>C.</B></KBD><KBD style=margin-left:18pt></KBD><B>War in Israel (continued):</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On February 28, 2026, the United States and Israel conducted coordinated aerial operations targeting military and governmental facilities in Iran. Subsequently, Iran launched missile attacks across parts of the Middle East and Hezbollah launched barrages of rockets toward northern Israel, leading to retaliatory actions by Israel. As of the date of these financial statements, hostilities in the region have intensified and involve multiple parties, including Israel, the United States, Iran and Hezbollah. As of the date of these unaudited interim condensed consolidated financial statements, a temporary ceasefire has been established between the parties to support ongoing negotiations toward a potential long-term agreement.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><A name=_Hlk175229040 />&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The evolving regional security situation has created and may continue to create significant uncertainty and could adversely affect Israel&#8217;s economy, the Company&#8217;s operations, employees, business partners, supply chain and overall business environment. The Company confirms that it has a business continuity plan and procedures in place, ensuring operational and financial continuity. As of the date of these unaudited interim condensed consolidated financial statements, the Company has not experienced a material adverse impact on its operations; however, the Company continues to monitor the situation closely and cannot predict the ultimate impact that these developments may have on its business, financial condition or results of operations and have implemented several measurements (e.g., remote work protocols/safety stock) to mitigate potential disruptions.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P style='font:12pt Times New Roman;margin:0'><B>NOTE 2 - BASIS OF PREPARATION:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>These unaudited interim condensed consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and Interpretations (collectively IFRS Accounting Standards). These interim unaudited condensed consolidated financial statements have been prepared in accordance with International Accounting Standards IAS 34 Interim Financial Reporting.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>These unaudited interim condensed consolidated financial statements do not include all the information required for annual consolidated financial statements and should be read in conjunction with the Company&#8217;s annual consolidated financial statements as of December 31, 2025. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2025, are applied consistently in these unaudited interim consolidated financial statements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><FONT style='border-bottom:1px solid #000000'><I>New IFRS Accounting Standards adopted in the period</I></FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company has not adopted any new IFRS Accounting Standards or amendments that are effective for the period beginning January 1, 2026.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><FONT style='border-bottom:1px solid #000000'><I>New IFRS Accounting Standards issued but not yet effective</I></FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements, which replaces IAS 1 Presentation of Financial Statements and includes consequential amendments to other IFRS Accounting Standards, including IAS 7, IAS 8, IAS 33 and IAS 34. IFRS 18 is effective for annual reporting periods beginning on or after January 1, 2027, with earlier application permitted. The Company has not early adopted IFRS 18. The Company is currently evaluating the impact of adopting IFRS 18 on its interim and annual consolidated financial statements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>9</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 3 - LOANS:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.3pt;margin-left:21.3pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:21.3pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.3pt'>A.</KBD>Short-term loans:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company borrowed funds from private investors under the following terms:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>1)</KBD>The Company will pay a 16% annual interest rate, with equal payments to be made monthly against both principal and interest.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.8pt;margin-left:36pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>2)</KBD>The Company will pay a 20% annual interest rate with a payment of both principal and interest at the end of the loan term.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Any loan amount will have a term of 12 months from the date the funds are received.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>A summary of movements of principal and interest during the three months ended March 31, 2026, is as follows:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:467.75pt;margin-left:21.3pt><TR style=height:11.9pt><TD valign=middle style='width:276.4pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:63.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>16%</B></P>
</TD><TD valign=middle style='width:63.75pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>20%</B></P>
</TD><TD valign=middle style='width:63.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Total</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:276.4pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance as of December 31, 2025</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>93</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.75pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri><B>-</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>93</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:276.4pt><P style='font:11pt Times New Roman;margin:0'>Accrued interest recognized in Profit or loss</P>
</TD><TD valign=middle style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri>1</FONT></P>
</TD><TD valign=middle style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri>1</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:276.4pt><P style='font:11pt Times New Roman;margin:0'>Repayment of principal and interest</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri>(94)</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri>(94)</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:276.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance as of March 31, 2026</B></P>
</TD><TD valign=middle style='width:63.8pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle style='width:63.75pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri><B>-</B></FONT></P>
</TD><TD valign=middle style='width:63.8pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:21.3pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.3pt'>B.</KBD>Returning investor notes:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company received funds under new loan facilities from investors who were offered the opportunity to participate, following their participation in a prior convertible loan that is no longer outstanding.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On April 11, 2025, the Company announced the first closing date of the offer and issued notes for an aggregate amount of $3,848.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On June 3, 2025, the Company announced the second closing date of the offer and issued notes for an aggregate amount of $77.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The loans bear interest at a rate of 5%, 10% and 12% per annum, paid on a quarterly or annually basis. The term of the loans is 24 months from the closing dates. Any accrued interest for the period between proceeds of the loans and issuance of the notes will be added to the principal amount of the notes as incremental principal.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>As additional compensation, the Company extended 503,033 Early Conversion Warrants, 257,143 Major Investor Warrants and 64,986 warrants that were accounted as shared based compensation held by the lenders for additional 24 months.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company accounted for these transactions in accordance with the treatment of an issuance of freestanding instruments issued together. Firstly, the Company measured the value of the liability loan component (principal and interest), at fair value. Secondly, the remainder of the transaction price was allocated to the hybrid instrument as an equity component which represents the value of the warrant extension for 24 months.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The initial adjustments to the fair value of the liability component were accounted for as discount debt to the notes and as an equity reserve. The discount debt is amortized to profit and loss on straight line basis over the contractual life of the notes to reflect its fair value at each reporting period.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>10</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 6 - LOANS (Continued)</B>:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.3pt;margin-left:21.3pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:21.3pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.3pt'>B.</KBD>Returning investor notes (continued):&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.3pt;margin-left:21.3pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:460.65pt;margin-left:21.3pt><TR style=height:17pt><TD valign=middle style='width:233.85pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>5%</B></P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>10%</B></P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>12%</B></P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Total</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.85pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance as of December 31, 2025</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>1,668</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>752</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>2,420</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.85pt><P style='font:11pt Times New Roman;margin:0'>Accrued interest recognized as incremental principal</P>
</TD><TD valign=middle style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>47</B></P>
</TD><TD valign=middle style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>21</B></P>
</TD><TD valign=middle style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>68</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:233.85pt><P style='font:11pt Times New Roman;margin:0'>Repayment of principal and interest</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>(47)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>(47)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.85pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Amortization of debt discount</P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>64</B></P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>13</B></P>
</TD><TD valign=middle style='width:56.7pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>77</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.85pt;border-top:1.5pt solid #000000;border-bottom:2.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance as of March 31, 2026</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000;border-bottom:2.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>-</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000;border-bottom:2.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>1,732</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000;border-bottom:2.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>786</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;border-top:1.5pt solid #000000;border-bottom:2.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><B>2,518</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The outstanding balance of the 10% loan is presented as short-term loan.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The outstanding balance of the 12% loan is presented as long-term loan.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:21.3pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.3pt'>C.</KBD>Convertible loan facility:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company received funds as part of a new convertible loan facility. In addition, existing lenders under the Short-term loans redeemed their outstanding loan balance of $573 by entering to the convertible loan facility, as well as pre-funded $200 entered to the convertible loan facility.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The convertible loan facility will bear interest at a rate of 8% per annum, paid on an annual basis. The term of the convertible loan is 36 months from the closing date (the &#8220;Maturity Date&#8221;). The lender may, at any time following 12 months from the closing date (the &#8220;First Anniversary&#8221;), prior to the Maturity Date, elect to convert any unconverted portion of the principal amount together with the accrued interest into common shares at the Conversion Price (as defined below).</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The conversion price is the price per share (the &#8220;Conversion Price&#8221;) that is equal to Closing Market Average (as defined below) of the Company&#8217;s common shares on the date of conversion less a discount of 20% but in any event not less than the Closing Market Price on the date of issuance (the &#8220;Floor Price&#8221;) and not higher than three times the Floor Price if converted after the First Anniversary and before 24 months following the closing date (the &#8220;Second Anniversary&#8221;) and five times the Floor Price if converted after the Second Anniversary.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The closing market average is the average of the published closing price (the &#8220;Closing Market Average&#8221;) of the common shares of the Company for the 20 days prior to conversion.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Any accrued interest for the period between proceeds of the funds and issuance of the convertible notes will be added to the principal amount of the convertible notes as incremental principal.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In case of an equity offering of not less than $1,000 is made by the Company (the &#8220;Equity Offering&#8221;) after the Closing Date, the holder will have the option to convert the entire principal amount and any interest accrued up to and including the closing date of the Equity Offering into common shares at the same price as the Equity Offering.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On September 19, 2025, the Company announced the first closing of $7,452 convertible loans.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On September 29, 2025, the Company announced the second closing of $151 convertible loans.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>11</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 6 - LOANS (Continued)</B>:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:21.3pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.3pt'>C.</KBD>Convertible loan facility (continued):&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On each closing date, the Company offered the convertible loan holders the opportunity to convert any unconverted portion of the principal amount together with the accrued interest into common shares at a conversion price of $6.50.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On September 19, 2025, the Company issued 1,146,474 common shares as a result of the conversion of $7,452 at a conversion price of $6.5.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>On September 29, 2025, the Company issued 23,284 common shares as a result of the conversion of $151 at a conversion price of $6.5.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company recorded finder&#8217;s fees of $503 in connection with the transactions.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:460.65pt;margin-left:21.3pt><TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:368.55pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance as of December 31, 2025</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:92.1pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>56</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:368.55pt><P style='font:11pt Times New Roman;margin:0'>Accrued interest recognized as incremental principal</P>
</TD><TD valign=middle style=width:92.1pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>1</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:368.55pt><P style='font:11pt Times New Roman;margin:0'>Repayment of outstanding balance (*)</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:92.1pt><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>(57)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:368.55pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Balance as of March 31, 2026</B></P>
</TD><TD valign=middle style='width:92.1pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>-</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:45pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-30.8pt'>(*)</KBD>The outstanding balance of the convertible loan was repaid to the investors prior to closing, and accordingly, no conversion into equity occurred.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>12</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:12pt Times New Roman;margin:0'><B>NOTE 4 - SHARE CAPITAL:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:481.9pt;margin-left:14.4pt><TR><TD valign=top style='width:226.75pt;border-bottom:1pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=2 valign=top style='width:255.15pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-8.25pt;margin-left:2.85pt'><B>Number of shares </B></P>
</TD></TR>
<TR><TD valign=top style='width:226.75pt;border-top:1pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:127.55pt;border-top:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'><B>March 31, 2026</B></P>
</TD><TD valign=bottom style='width:127.6pt;border-top:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'><B>December 31, 2025</B></P>
</TD></TR>
<TR><TD valign=top style='width:226.75pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:127.55pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'><B>Issued and outstanding</B></P>
</TD><TD valign=top style='width:127.6pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt'><B>Issued and outstanding</B></P>
</TD></TR>
<TR style=height:25pt><TD valign=middle bgcolor=#DBE5F1 style='width:226.75pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0;color:#000000'>Common shares</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:127.55pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'><FONT style=font-family:Calibri><B>22,667,842</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:127.6pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'><FONT style=font-family:Calibri>22,666,842</FONT></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><I>Ordinary Shares:</I></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Ordinary Shares confer upon their holders, the right to receive notice of, and to participate in, all general meetings of the Company, to vote in such meetings, to receive dividends, and to participate in the distribution of the surplus assets of the Company in the event of liquidation of the Company.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%;margin-left:14.4pt><TR><TD valign=top bgcolor=#DBE5F1 style='width:361.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt'><B>Balance as of December 31, 2024</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'><B>17,327,716</B></P>
</TD></TR>
<TR><TD valign=top style='width:361.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt'>Issuance of shares upon vesting of RSUs</P>
</TD><TD valign=top style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000'><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'>11,114</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:361.5pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt;color:#000000'>Exercise of investor warrants</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:127.55pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'>1,291,523</P>
</TD></TR>
<TR><TD valign=top style=width:361.5pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt;color:#000000'>Issuance of shares in public offering</P>
</TD><TD valign=top style=width:127.55pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'>2,846,854</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:361.5pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt;color:#000000'>Exercise of employee and consultant stock options and warrants</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:127.55pt;padding-left:1.4pt;padding-right:1.4pt><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'>19,877</P>
</TD></TR>
<TR><TD valign=top style='width:361.5pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt'>Conversion of convertible loans into equity</P>
</TD><TD valign=top style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'>1,169,758</P>
</TD></TR>
<TR style=height:13.55pt><TD valign=top bgcolor=#DBE5F1 style='width:361.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt'><B>Balance as of December 31, 2025</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'><B>22,666,842</B></P>
</TD></TR>
<TR style=height:13.55pt><TD valign=top style='width:361.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt'>Issuance of shares upon vesting of RSUs (Note 4b)</P>
</TD><TD valign=top style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'>1,000</P>
</TD></TR>
<TR style=height:13.55pt><TD valign=top bgcolor=#DBE5F1 style='width:361.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;text-indent:-22.6pt;margin-left:28.35pt'><B>Balance as of March 31, 2026</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=right style='font:11pt Calibri;margin:0;margin-right:14.2pt'><B>22,667,842</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>a.</KBD>The Company is authorized to issue an unlimited number of common shares.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.8pt;margin-left:36pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>b.</KBD>During February 2026 the Company issued 1,000 common shares in lieu of vested RSUs.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.8pt;margin-left:36pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>c.</KBD>The following table summarizes information about the warrants outstanding as of March 31, 2026:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:460.65pt;margin-left:21.3pt><TR style=height:13.65pt><TD colspan=5 valign=middle style='width:460.65pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Warrants Outstanding</B></P>
</TD></TR>
<TR style=height:26.95pt><TD valign=middle style='width:141.75pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>March 31, 2026</B></P>
</TD><TD valign=middle style='width:14.15pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:148.85pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Exercise Price</B></P>
</TD><TD valign=middle style='width:14.15pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:141.75pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Expiry Date</B></P>
</TD></TR>
<TR style=height:14.45pt><TD valign=top bgcolor=#DBE5F1 style='width:141.75pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>257,143</FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:14.15pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:148.85pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>$7.77</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:14.15pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:141.75pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>October 30, 2027</P>
</TD></TR>
<TR style=height:14.45pt><TD valign=top style=width:141.75pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>276,567</FONT></P>
</TD><TD valign=top style=width:14.15pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:148.85pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>$7.77 </P>
</TD><TD valign=top style=width:14.15pt><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=top style=width:141.75pt><P align=center style='font:11pt Times New Roman;margin:0'>October 30, 2027</P>
</TD></TR>
<TR style=height:14.45pt><TD valign=top bgcolor=#DBE5F1 style='width:141.75pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>22,994</FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:14.15pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:148.85pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>$7.77 </P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:14.15pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:141.75pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>December 22, 2027</P>
</TD></TR>
<TR style=height:14.45pt><TD valign=top style='width:141.75pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri><B>556,704</B></FONT></P>
</TD><TD valign=top style='width:14.15pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:148.85pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>-</P>
</TD><TD valign=top style='width:14.15pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:141.75pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>13</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 5 - SHARE BASED COMPENSATION:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B><I>Stock Options awards under Equity Incentive Plan:</I></B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>a.</KBD>Options granted under the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;Plan&#8221;) are exercisable within 10 years from the date of grant upon payment of the exercise price as indicated in the Plan.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>b.</KBD>On March 13, 2026, the Company granted employees, consultants and directors 603,219 options to purchase shares of the Company at $4.15 per share under the Company&#8217;s plan. The options will vest quarterly over a 3-year period. The total value of the options granted is $1,460,318.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>c.</KBD>During the three-month period ended March 31, 2026, the Company recognized share-based compensation expense related to stock options in the amount of $189.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>d.</KBD>The following assumptions were used to estimate the fair value of the options using the Black-Scholes model:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:467.75pt;margin-left:14.4pt><TR><TD valign=middle style='width:291.35pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:1.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:84.95pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>Three months ended March 31, 2026</B></P>
</TD><TD valign=top style='width:91.45pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'><B>For the year ended December 31, 2025</B></P>
</TD></TR>
<TR><TD valign=middle bgcolor=#DBE5F1 style='width:291.35pt;padding-left:5.4pt;padding-right:5.4pt;border-top:1.5pt solid #000000'><P style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>Volatility</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:84.95pt;padding-left:5.4pt;padding-right:5.4pt;border-top:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>60%</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:91.45pt;padding-left:5.4pt;padding-right:5.4pt;border-top:1.5pt solid #000000'><P align=center style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>50%-60%</FONT></P>
</TD></TR>
<TR><TD valign=middle style=width:291.35pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>Dividend Yield</FONT></P>
</TD><TD valign=middle style=width:84.95pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:10pt Times New Roman;margin:0'>0%</P>
</TD><TD valign=middle style=width:91.45pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>0%</FONT></P>
</TD></TR>
<TR style=height:3.5pt><TD valign=middle bgcolor=#DBE5F1 style='width:291.35pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>Risk-Free Interest Rate</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:84.95pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>3.88%-4.02%</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:91.45pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>3.71%-3.97%</FONT></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.8pt;margin-left:36pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>e.</KBD>A summary of activity of options granted under the Company&#8217;s Plan is as follows:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-21.8pt;margin-left:36pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:460.65pt;margin-left:14.4pt><TR><TD valign=middle style=width:205.5pt;padding-left:1.4pt;padding-right:1.4pt rowspan='2'><P style='font:11pt Times New Roman;margin:0;margin-left:28.35pt'>&nbsp;</P>
</TD><TD colspan=2 valign=top style='width:127.6pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>March 31, 2026</B></P>
</TD><TD colspan=2 valign=top style='width:127.55pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>December 31, 2025</B></P>
</TD></TR>
<TR><TD valign=bottom style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Number of Options</B></P>
</TD><TD valign=bottom style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:1.4pt'><B>Weighted Average Exercise Price ($)</B></P>
</TD><TD valign=bottom style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Number of Options</B></P>
</TD><TD valign=bottom style='width:63.75pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:1.4pt'><B>Weighted Average Exercise Price ($)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:205.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Options outstanding at beginning of period</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>1,980,562</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>6.32</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>1,902,090</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.75pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>6.30</B></FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:205.5pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'><B>Changes during the period:</B></P>
</TD><TD valign=middle style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:63.75pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:205.5pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'><FONT style=font-family:Calibri>Granted (Note 5b)</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>603,219</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>4.15</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>104,425</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:63.75pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>8.07</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:205.5pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Exercised</P>
</TD><TD valign=middle style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle style=width:63.8pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>(8,929)</FONT></P>
</TD><TD valign=middle style=width:63.75pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>4.04</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:205.5pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Forfeited</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>(17,024)</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.75pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6.79</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:205.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Options outstanding at end of period</B></P>
</TD><TD valign=middle style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>2,583,781</B></FONT></P>
</TD><TD valign=middle style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>5.81</B></FONT></P>
</TD><TD valign=middle style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>1,980,562</B></FONT></P>
</TD><TD valign=middle style='width:63.75pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>6.32</B></FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:205.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Options exercisable at period end</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>1,783,447</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6.25</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.8pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>1,749,670</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:63.75pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6.24</FONT></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The options outstanding as of March 31, 2026, had a weighted-average contractual life of 6.55 years (December 31, 2025: 5.75 years).</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>14</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><FONT style=font-size:12pt><B>NOTE </B><B>5</B><B> </B></FONT><B>-</B><FONT style=font-size:12pt><B> SHARE BASED </B><B>COMPENSATION </B><B>(Continued)</B></FONT>:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B><I>Restricted Stock Units (RSUs) Awards under Equity Incentive Plan:</I></B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>f.</KBD>RSUs granted under the Company&#8217;s 2025 Equity Incentive Plan (the &#8220;Plan&#8221;) are settled in common shares upon completion of the applicable vesting and performance conditions.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>g.</KBD>On March 13, 2026, the Company granted employees, consultants and directors 262,830 RSUs under the Company&#8217;s plan. The RSUs will vest quarterly over a 3-year period.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>h.</KBD>During the three-month period ended March 31, 2026, the Company recognized share-based compensation expense related to restricted stock units in the amount of $27.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>i.</KBD>A summary of activity of RSUs granted under the Company&#8217;s Plan is as follows:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:460.65pt;margin-left:14.4pt><TR style=height:11.9pt><TD valign=middle style=width:233.85pt;padding-left:1.4pt;padding-right:1.4pt rowspan='2'><P style='font:11pt Times New Roman;margin:0;margin-left:28.35pt'>&nbsp;</P>
</TD><TD colspan=2 valign=bottom style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>March 31, 2026</B></P>
</TD><TD colspan=2 valign=bottom style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>December 31, 2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Number of RSUs</B></P>
</TD><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:1.4pt'><B>Weighted Average Exercise Price ($)</B></P>
</TD><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Number of RSUs</B></P>
</TD><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:1.4pt'><B>Weighted Average Exercise Price ($)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:233.85pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>RSUs outstanding at beginning of period</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>6,400</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>5.97</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>25,400</B></FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6.51</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:233.85pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:2.85pt;margin-right:2.85pt'><B>Changes during the period:</B></P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:233.85pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Granted (Note 5g)</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>262,830</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>4.15</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6,400</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>5.97</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:233.85pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Issued (Note 4b)</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>(1,000)</FONT></P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>5.97</FONT></P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>(11,114)</FONT></P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6.34</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:233.85pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Forfeited</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>-</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>(14,286)</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri>6.64</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:233.85pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>RSUs outstanding at end of period</B></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>268,230</B></FONT></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>4.19</B></FONT></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>6,400</B></FONT></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><FONT style=font-family:Calibri><B>5.97</B></FONT></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B><I>Warrants Issued to Service Providers:</I></B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>j.</KBD>The following assumptions were used to estimate the fair value of the warrants using the Black-Scholes model:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:467.75pt;margin-left:14.4pt><TR><TD valign=middle style=width:291.85pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:85.1pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>Three months ended March 31, 2026</B></P>
</TD><TD valign=top style=width:90.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>For the year ended December 31, 2025</B></P>
</TD></TR>
<TR><TD valign=middle bgcolor=#DBE5F1 style='width:291.85pt;padding-left:5.4pt;padding-right:5.4pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Volatility</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:85.1pt;padding-left:5.4pt;padding-right:5.4pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:90.8pt;padding-left:5.4pt;padding-right:5.4pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>59%</P>
</TD></TR>
<TR><TD valign=middle style=width:291.85pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>Dividend Yield</P>
</TD><TD valign=middle style=width:85.1pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=middle style=width:90.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'>0%</P>
</TD></TR>
<TR style=height:3.5pt><TD valign=middle bgcolor=#DBE5F1 style='width:291.85pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Risk-Free Interest Rate</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:85.1pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:90.8pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4.21%</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>15</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><FONT style=font-size:12pt><B>NOTE 5 </B></FONT><B>-</B><FONT style=font-size:12pt><B> SHARE BASED COMPENSATION (Continued)</B></FONT>:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>k.</KBD>A summary of activity of warrants granted to purchase the Company&#8217;s Shares under the Company&#8217;s Plan is as follows:&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:467.75pt;margin-left:14.4pt><TR style=height:11.9pt><TD valign=middle style=width:240.95pt;padding-left:1.4pt;padding-right:1.4pt rowspan='2'><P style='font:11pt Times New Roman;margin:0;margin-left:28.35pt'>&nbsp;</P>
</TD><TD colspan=2 valign=bottom style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>March 31, 2026</B></P>
</TD><TD colspan=2 valign=bottom style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:1pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><B>December 31, 2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Number of Warrants</B></P>
</TD><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:1.4pt'><B>Weighted Average Exercise Price ($)</B></P>
</TD><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:2.85pt'><B>Number of Warrants</B></P>
</TD><TD valign=bottom style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:1pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:2.85pt;margin-right:1.4pt'><B>Weighted Average Exercise Price ($)</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:240.95pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Warrants outstanding at beginning of period</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>62,609</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>7.54</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>73,557</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>7.54</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:240.95pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:2.85pt;margin-right:2.85pt'><B>Changes during the period:</B></P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-2.85pt;margin-left:5.65pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:240.95pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Issued</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:240.95pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Exercised</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>(10,948)</P>
</TD><TD valign=middle style=width:56.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>7.66</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:240.95pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt'>Expired</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'>-</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:240.95pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Warrants outstanding at end of period</B></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>62,609</B></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>7.54</B></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>62,609</B></P>
</TD><TD valign=middle style='width:56.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-10.35pt;margin-left:5.65pt'><B>7.54</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-21.8pt'>l.</KBD>The following table summarizes information about the warrants outstanding as of March 31, 2026::&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:460.65pt;margin-left:14.4pt><TR style=height:11.9pt><TD colspan=3 valign=middle style='width:460.65pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Warrants Outstanding</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:155.9pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>March 31, 2026</B></P>
</TD><TD valign=middle style='width:148.85pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Exercise Price</B></P>
</TD><TD valign=middle style='width:155.9pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Expiry Date</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:155.9pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>54,038</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:148.85pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>$7.66</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:155.9pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>October 25, 2027</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style='width:155.9pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>8,571</P>
</TD><TD valign=top style='width:148.85pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>$6.66</P>
</TD><TD valign=top style='width:155.9pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>April 26, 2026</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:155.9pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>62,609</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:148.85pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:155.9pt;border-top:1.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 6 - LIABILITY FOR AGRICULTURAL RESEARCH ORGANIZATION:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In March 2007, the Company entered into a Research and Exclusive License Agreement (the &#8220;Agreement&#8221;) with The Agricultural Research Organization &#8211;&nbsp;Volcani Institute (the &#8220;ARO&#8221;). The ARO granted the Company an exclusive worldwide license to use its patent as part of the manufacturing of red grape cell powder only. The ARO is entitled to receive 3% royalties from any sale of red grape cell powder products by the Company until the end of February 2026.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In September 2025, the Company and ARO executed an amendment to the existing agreement effective from January 2025, establishing updated payment terms. Under the revised terms, the total amount payable was set at $3,600. The Company is required to remit minimum quarterly payments of 1% of its quarterly revenue from sales of red grape cell powder products only. Such minimum payments were $79 for the first quarter of 2025, $96 for the second quarter of 2025, $105 for the third quarter of 2025, $115 for the fourth quarter of 2025, and will be $120 for each quarter thereafter through the first quarter of 2026 until the total payable amount is fully settled. Accordingly, the Company reassessed and remeasured the related liability to reflect the amended terms.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>16</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 7 - RELATED PARTIES TRANSACTIONS:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Related parties including the Company&#8217;s CEO, CFO, Chairman of the Board and Directors.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Related party transactions:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:467.1pt;margin-left:14.4pt><TR style=height:14.15pt><TD valign=middle style=width:308.4pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0'><B>For the year ended December,</B></P>
</TD><TD colspan=2 valign=bottom style=width:158.7pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>Three months ended March 31,</B></P>
</TD></TR>
<TR style=height:14.15pt><TD valign=middle style=width:308.4pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:83.1pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>2026</B></P>
</TD><TD valign=top style=width:75.6pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:308.4pt;padding-left:2.8pt;padding-right:2.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Compensation for key management personnel of the Company:</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:83.1pt;padding-left:2.8pt;padding-right:2.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:75.6pt;padding-left:2.8pt;padding-right:2.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:308.4pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0'>Management fees</P>
</TD><TD valign=middle style=width:83.1pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>475</B></P>
</TD><TD valign=middle style=width:75.6pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'>455</P>
</TD></TR>
<TR style=height:12.35pt><TD valign=middle bgcolor=#DBE5F1 style=width:308.4pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0'>Share based payments</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:83.1pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>50</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:75.6pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>7</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Related party balances:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:481.95pt;margin-left:14.4pt><TR style=height:11.9pt><TD valign=middle style='width:311.85pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:85.05pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>March 31,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'><B>2026</B></P>
</TD><TD valign=bottom style='width:85.05pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>December 31,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'><B>2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:311.85pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0;margin-left:4.4pt'><B>Due to key management personnel of the Company:</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:85.05pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:85.05pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:311.85pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0;margin-left:4.4pt'>Management fees</P>
</TD><TD valign=middle style=width:85.05pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>337</B></P>
</TD><TD valign=middle style=width:85.05pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>227</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:311.85pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0;margin-left:4.4pt'>Prepaid expenses</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:85.05pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>(26)</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:85.05pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>(26)</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 8 - OPERATING SEGMENTS:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Effective January 1, 2024, the Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company service lines representing its main products and services.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company&#8217;s chief operating decision maker reviews the Company&#8217;s internal reports for performance evaluation and resource allocations. The Company&#8217;s management determined the operating segments based on these reports. The chief operating decision maker examines the performance of the operating segments based on the measurement of operating profit. No information was presented on the assets and liabilities of the segments because these items are not analyzed by the main operational decision maker in segmentation.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company&#8217;s chief operating decision maker is the Chief Executive Officer. For further details on the change in the Chief Executive Officer that occurred subsequent to the reporting date, refer to Note 10.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Segment description:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-27pt'><B>1.</B></KBD><B>The Products Business Unit</B> - Nutraceuticals: Marketing and sales of science-based health and wellness nutraceutical solutions, sold as dietary supplements, functional food and beverages (capsules, powders, chews, coffee, teas and powder electrolyte beverages). The Products Business Unit sources its red grape cell powder from the CDMO Services Business Unit, it then uses other third-party manufacturers and contractors to encapsulate, integrate, package and ship the finished product for the direct sale to end consumers.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-27pt'><B>2.</B></KBD><B>The CDMO Services Business Unit</B> - A Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;) providing end-to-end development and manufacturing services for plant-based active molecules to pharmaceuticals, cosmeceuticals, nutraceuticals and nutrition customers. The CDMO serves both the Company&#8217;s Products Business Unit (as its exclusive manufacturer of VINIA&#174; red grape cell powder) and external customers from the pharmaceutical, cosmeceutical, nutraceutical and nutrition industries.&nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>17</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 8 - OPERATING SEGMENTS (Continued):</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Change in the measurement of segment profit (loss)</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Effective January 1, 2026, following a change in the Company&#8217;s organizational structure and internal management reporting lines, the Company modified the basis on which segment operating profit (loss) is measured and reviewed by the CODM. Specifically, certain revenues and operating expenses (including cost of goods, research and development, sales and marketing and general and administrative), which were previously allocated to segments based on reporting lines, are now allocated to the operating segments based on direct attribution to the relevant business unit in accordance with the revised management reporting lines, a measure of resource consumption, headcount or a revenue-based key.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The revised measurement basis reflects the adoption of an arm&#8217;s length approach, whereby inter-segment revenues and the allocation of shared costs between the operating segments are determined on terms that would apply between parties acting at arm&#8217;s length, consistent with the manner in which performance is now reviewed by the CODM.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The change did not affect the identification of the Company&#8217;s reportable segments, which continue to be the Products business unit and the CDMO Services business unit, nor does it affect the Company&#8217;s consolidated revenues, operating loss, net loss or financial position. The change affects only the allocation of revenues and operating expenses, and accordingly the measurement of segment operating profit (loss), among the existing segments.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In accordance with IFRS 8, comparative segment information for the three months ended March 31, 2025, has been restated to conform to the current period&#8217;s measurement basis. The restatement has no impact on the Company&#8217;s previously issued financial statements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>18</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 8 - OPERATING SEGMENTS (Continued):</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Segment information:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%;margin-left:14.4pt><TR><TD valign=top style='width:173.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=4 valign=bottom style='width:308.15pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>For the three months ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:76.9pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>CDMO Services</B></P>
</TD><TD valign=bottom style='width:77.05pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Products</B></P>
</TD><TD valign=bottom style='width:77.45pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Elimination of inter-segment transactions</B></P>
</TD><TD valign=bottom style='width:76.75pt;border-top:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Total</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Revenues</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>External</P>
</TD><TD valign=top style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>409</P>
</TD><TD valign=top style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>8,098</P>
</TD><TD valign=top style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>8,507</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Inter-segment</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1,999</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1,999)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment revenues</B></P>
</TD><TD valign=top style='width:76.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2,408</B></P>
</TD><TD valign=top style='width:77.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>8,098</B></P>
</TD><TD valign=top style='width:77.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,999)</B></P>
</TD><TD valign=top style='width:76.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>8,507</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'><B>Cost of revenues</B></P>
</TD><TD valign=top style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>External</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>(2,143)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>(1,327)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(3,470)</P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Inter-segment</P>
</TD><TD valign=top style='width:76.9pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style='width:77.05pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1,999)</P>
</TD><TD valign=top style='width:77.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1,999</P>
</TD><TD valign=top style='width:76.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment cost of revenues</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(2,143)</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(3,326)</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>1,999</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(3,470)</B></P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.9pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.05pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.45pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.75pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment gross profit</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>265</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>4,772</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>-</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>5,037</B></P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment gross margin</B></P>
</TD><TD valign=top style='width:76.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>11.00%</P>
</TD><TD valign=top style='width:77.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>58.93%</P>
</TD><TD valign=top style='width:77.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:76.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>59.21%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'><B>Operating expenses</B></P>
</TD><TD valign=top style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>Research and development</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>(1,226)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>(168)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(1,394)</P>
</TD></TR>
<TR><TD valign=top style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>Sales and marketing</P>
</TD><TD valign=top style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>(57)</P>
</TD><TD valign=top style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>(4,069)</P>
</TD><TD valign=top style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(4,126)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>General and administrative</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(265)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1,086)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1,351)</P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment total operating expenses</B></P>
</TD><TD valign=top style='width:76.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,548)</B></P>
</TD><TD valign=top style='width:77.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(5,323)</B></P>
</TD><TD valign=top style='width:77.45pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>-</B></P>
</TD><TD valign=top style='width:76.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(6,871)</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment operating profit (loss)</B></P>
</TD><TD valign=top style='width:76.9pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,283)</B></P>
</TD><TD valign=top style='width:77.05pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(551)</B></P>
</TD><TD valign=top style='width:77.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>-</B></P>
</TD><TD valign=top style='width:76.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,834)</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.8pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.9pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.05pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.45pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>Finance income</P>
</TD><TD valign=top style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>114</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>Finance expenses</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(875)</P>
</TD></TR>
<TR><TD valign=top style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>Taxes on income</P>
</TD><TD valign=top style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(46)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.8pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.9pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.05pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.45pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:173.8pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri><B>Net loss and comprehensive loss</B></FONT></P>
</TD><TD valign=top style='width:76.9pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.05pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.45pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.75pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(2,641)</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>19</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 8 - OPERATING SEGMENTS (Continued):</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Segment information (continued):</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%;margin-left:14.4pt><TR><TD valign=top style='width:173.65pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=4 valign=bottom style='width:308.3pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>For the three months ended March 31, 2025 (*)</B></P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-top:1.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:76.95pt;border-top:1.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>CDMO Services</B></P>
</TD><TD valign=bottom style='width:77.1pt;border-top:1.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Products</B></P>
</TD><TD valign=bottom style='width:77.5pt;border-top:1.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Elimination of inter-segment transactions</B></P>
</TD><TD valign=bottom style='width:76.75pt;border-top:1.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Total</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Revenues</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-top:0.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-top:0.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-top:0.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>External</P>
</TD><TD valign=top style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>170</P>
</TD><TD valign=top style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>7,690</P>
</TD><TD valign=top style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>7,860</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Inter-segment</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,021</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(2,021)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment revenues</B></P>
</TD><TD valign=top style='width:76.95pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2,191</B></P>
</TD><TD valign=top style='width:77.1pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>7,690</B></P>
</TD><TD valign=top style='width:77.5pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(2,021)</B></P>
</TD><TD valign=top style='width:76.75pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>7,860</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'><B>Cost of revenues</B></P>
</TD><TD valign=top style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>External</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>(2,172)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>(1,093)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(3,265)</P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Inter-segment</P>
</TD><TD valign=top style='width:76.95pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:77.1pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(2,021)</P>
</TD><TD valign=top style='width:77.5pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,021</P>
</TD><TD valign=top style='width:76.75pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment cost of revenues</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(2,172)</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(3,114)</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2,021</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(3,265)</B></P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.95pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.1pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.5pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.75pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment gross profit</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>19</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>4,576</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>-</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>4,595</B></P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment gross margin</B></P>
</TD><TD valign=top style='width:76.95pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.1pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.5pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.75pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'><B>Operating expenses</B></P>
</TD><TD valign=top style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>Research and development</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>(1,110)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>(135)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(1,245)</P>
</TD></TR>
<TR><TD valign=top style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>Sales and marketing</P>
</TD><TD valign=top style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>(95)</P>
</TD><TD valign=top style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>(3,586)</P>
</TD><TD valign=top style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(3,681)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>General and administrative</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(84)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1,304)</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1,388)</P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment total operating expenses</B></P>
</TD><TD valign=top style='width:76.95pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,289)</B></P>
</TD><TD valign=top style='width:77.1pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(5,025)</B></P>
</TD><TD valign=top style='width:77.5pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>-</B></P>
</TD><TD valign=top style='width:76.75pt;border-top:0.25pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(6,314)</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment operating profit (loss)</B></P>
</TD><TD valign=top style='width:76.95pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,270)</B></P>
</TD><TD valign=top style='width:77.1pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(449)</B></P>
</TD><TD valign=top style='width:77.5pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>-</B></P>
</TD><TD valign=top style='width:76.75pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(1,719)</B></P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style='width:173.65pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.95pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.1pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:77.5pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:76.75pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>Finance income</P>
</TD><TD valign=top style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>Finance expenses</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(581)</P>
</TD></TR>
<TR><TD valign=top style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>Taxes on income</P>
</TD><TD valign=top style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>(38)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#DBE5F1 style=width:173.65pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.95pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.1pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:77.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:76.75pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:173.65pt;border-bottom:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Segment net profit (loss)</B></P>
</TD><TD valign=top style='width:76.95pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.1pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:77.5pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:76.75pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(2,338)</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>(*) Comparative figures have been restated to reflect the current period&#8217;s presentation and measurement.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Entity wide disclosures</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:479.1pt><TR><TD valign=top style=width:252.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>External revenue by location</B></P>
</TD><TD colspan=2 valign=top style='width:226.8pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>For the three months ended March 31,</B></P>
</TD></TR>
<TR><TD valign=top style=width:252.3pt;padding-left:1.4pt;padding-right:1.4pt><P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2026</B></P>
</TD><TD valign=top style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2025</B></P>
</TD></TR>
<TR><TD valign=middle bgcolor=#DBE5F1 style='width:252.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Israel</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:11.35pt;margin-right:11.35pt'>964</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:11.35pt;margin-right:11.35pt'>643</P>
</TD></TR>
<TR><TD valign=middle style='width:252.3pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>North America</P>
</TD><TD valign=top style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:11.35pt;margin-right:11.35pt'>7,543</P>
</TD><TD valign=top style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:11.35pt;margin-right:11.35pt'>7,217</P>
</TD></TR>
<TR><TD valign=middle bgcolor=#DBE5F1 style='width:252.3pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:11.35pt;margin-right:11.35pt'><B>8,507</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:113.4pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-left:11.35pt;margin-right:11.35pt'>7,860</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'><B>Additional information about revenue</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>There is no single customer for which revenue amounts to 10% or more of total revenue reported in these financial statements for the three and nine months ended March 31, 2026, and 2024.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>20</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:481.95pt><P align=justify style='font:12pt Times New Roman;margin:0;color:#000000'><FONT style=font-size:14pt><B>BioHarvest Sciences Inc.</B> <B>and its subsidiaries</B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:481.95pt><P align=justify style='font:11pt Times New Roman;margin:0'><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>For the Three Months Ended March 31, 2026</B></P>
</TD></TR>
<TR><TD valign=top style='width:481.95pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:11pt Times New Roman;margin:0'><B>(USD in thousands, except per share data)</B></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 9 - GOVERNMENT GRANTS:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In December 2025, the Company received approval from the Israel Innovation Authority (&#8220;IIA&#8221;) for a government grant under a research and development support program aimed to expand and improve the Company&#8217;s production capacity and efficiency (the &#8220;R&amp;D support program&#8221;). The approved project covers a period of 24 months commencing on October 1, 2025, with a total approved budget of NIS 14 million. Under the terms of grant, the Company is entitled to receive funding for up to 40% of the approved project budget.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In accordance with the IIA program requirements, the grant is conditionally repayable through the payment of royalties based on future revenues that may be generated from products developed as part of the supported project. Royalty payments, if any, will commence only upon the generation of revenues derived from the project&#8217;s outputs, and will continue until the full amount of the grant (plus applicable interest as determined by the IIA regulations) has been repaid, or until the statutory repayment cap has been met.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>In January 2026, the Company received its first advance payment of NIS 980 ($309), which was classified as deferred income.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>Based on management&#8217;s assessment and in accordance with the terms of the approval, the Company believes it is entitled to receive a grant equal to 40% of eligible costs incurred. The incurred costs as of March 31, 2026, amounted to approximately NIS 1,000 ($316).</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company recognized a royalty obligation reflecting the conditional repayment mechanism of the grant through future royalty payments.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:12pt Times New Roman;margin:0'><B>NOTE 10 - SUBSEQUENT EVENTS:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>The Company has evaluated events occurring after the balance sheet date through May 14, 2026, the date the unaudited interim condensed consolidated financial statements were issued, and has determined that the following subsequent events require disclosure:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-27pt'>1)</KBD>On April 29, 2026, the Company announced a strategic leadership transition were Dr. Zaki Rakib, the Chairman, assumed the role of Chief Executive Officer and Ilan Sobel, who served as Chief Executive Officer since 2020, transitioned from his executive role and was appointed to the Company&#8217;s Board of Directors.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-27pt;margin-left:54pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-27pt'>2)</KBD>On May 12, 2026, the Company signed an amendment to its lease agreement with Shugart Ltd., extending the lease term for an additional 12 months, from September 2026 through August 2027.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'>21</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>bhsc_ex992.htm
<DESCRIPTION>MANAGEMENT'S DISCUSSION AND ANALYSIS
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2026 [PPXC4Y912124VAJXLJL1]. www.edgarsuite.com -->
<HEAD>
<TITLE>Management's Discussion and Analysis</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:90pt;width:432pt><P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><IMG src=bhscex992_1.jpg width=548 height=105 alt='Picture 2' title='Picture 2'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:16pt Times New Roman;margin-top:6pt;margin-bottom:6pt;color:#000000'><FONT style=font-size:24pt><B>BioHarvest Sciences Inc.</B></FONT></P>
<P align=center style='font:16pt Calibri;margin-top:6pt;margin-bottom:6pt;color:#000000'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=center style='font:16pt Calibri;margin:0;color:#000000'><B>For the three months ended March 31, 2026</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><FONT style='font:14pt Calibri'><B>(Expressed in U.S. dollars)</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>Dated March 31, 2026</P>
<P align=justify style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>1140-625 Howe Street, Vancouver</P>
<P align=center style='font:10pt Times New Roman;margin:0'>British Columbia V6C 2T6, Canada</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>www.bioharvest.com</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Introduction</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The following Management's Discussion and Analysis (&#8221;MD&amp;A&#8221;) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries (&#8220;BioHarvest Sciences&#8221; or the &#8220;Company&#8221;) prepared as of May 14, 2026, and in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board and Interpretations (collectively IFRS Accounting Standards). All amounts (other than per share amounts) are stated in U.S dollars rounded to the nearest thousand, unless otherwise indicated.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The following information should be read in conjunction with the audited consolidated financial statements of the Company (the &#8220;consolidated financial statements&#8221;) for the year ended December 31, 2025, and the related notes to those financial statements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Statements in this report that are not historical facts are forward-looking statements involving known and unknown risks and uncertainties, which could cause actual results to vary considerably from these statements. Readers are cautioned not to put undue reliance on forward-looking statements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company is publicly listed and traded on the Nasdaq Stock Market under the symbol BHST and traded on the Frankfurt Stock Exchange, Munich Stock Exchange, Stuttgart Stock Exchange and Dusseldorf Stock Exchange under the symbol 8MV0.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Continuous disclosure materials are available on our website at <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>www.bioharvest.com</FONT>. This additional information is not incorporated into this Management's Discussion and Analysis and does not constitute a part of this Management's Discussion and Analysis.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>1</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Cautionary statement regarding forward-looking statements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>This MD&amp;A contains certain information that may constitute &#8220;forward-looking information&#8221; and &#8220;forward-looking statements&#8221; (collectively, &#8220;forward-looking statements&#8221;) which are based upon the Company&#8217;s current internal expectations, estimates, projections, assumptions and beliefs. Such statements can be identified by the use of forward-looking terminology such as &quot;expect,&quot; &#8220;likely&#8221;, &quot;may,&quot; &quot;will,&quot; &quot;should,&quot; &quot;intend,&quot; or &quot;anticipate&quot;, &#8220;potential&#8221;, &#8220;proposed&#8221;, &#8220;estimate&#8221; and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions &#8220;may&#8221; or &#8220;will&#8221; happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements included in this MD&amp;A are made only as of the date of this MD&amp;A. Forward-looking statements in this MD&amp;A may include, but are not limited to, statements with respect to: a) licensing risks; b) regulatory risks; c) change in laws, regulations and guidelines; d) market risks; e) expansion of facilities; f) history of net losses; and g) competition. Certain of the forward-looking statements and forward-looking information and other information contained herein concerning the, nutraceutical, pharmaceutical and cosmeceutical industries, the general expectations of the Company concerning these industries and concerning the Company are based on estimates prepared by the Company using data from publicly available governmental sources, from market research and industry analysis and on assumptions based on data and knowledge of these industries, &nbsp;which the Company believes to be reasonable. The Company is not aware of any misstatement regarding any industry or government data presented herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company&#8217;s forward-looking statements are expressly qualified in their entirety by this cautionary statement. In particular, but without limiting the foregoing, disclosure in this MD&amp;A under &#8220;Nature of the Business and Overview of Operations&#8221; as well as statements regarding the Company&#8217;s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. See &#8220;Risk and Uncertainties&#8221; for further details. The purpose of forward-looking statements is to provide the reader with a description of management&#8217;s expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not place undue reliance on forward- looking statements contained in this MD&amp;A. The Company undertakes no obligation to update or revise any forward-looking statements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>2</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Going concern</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The unaudited interim condensed consolidated financial statements have been prepared on a going concern basis in accordance with IFRS Accounting Standards. Management has evaluated the Company's ability to continue as a going concern for a period of at least twelve months from the date these unaudited interim condensed consolidated financial statements are issued.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company has a history of operating losses and has not yet achieved sustained cash-flow profitability. For the three-month period ended March 31, 2026, the Company generated revenues of $8,507 and incurred a net operating loss. As of March 31, 2026, the Company had cash and cash equivalents of $19,167. These conditions, together with the need for continued investment in operations and the uncertainty regarding the timing and availability of additional financing, represent factors that raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company may require additional capital to fund its long-term growth strategy and planned capital investments. If required, the Company intends to raise such capital through one or more of the following: the issuance of equity or equity-linked securities, debt financing, strategic collaborations, licensing arrangements or other financing transactions. The Company is listed on the Nasdaq Capital Market and has previously demonstrated access to the capital markets; however, there can be no assurance that additional financing will be available on acceptable terms, or at all.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Based on management&#8217;s assessment, the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, despite the factors noted above, the going concern basis of preparation remains appropriate, and these consolidated financial statements do not include any adjustments that might result from the outcome of uncertainties related to the going concern assessment.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The unaudited interim condensed consolidated financial statements of the Company were authorized for issue by the Board of Directors on May 14, 2026.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>3</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>NATURE OF BUSINESS AND </B><B>OVERVIEW OF OPERATIONS</B></FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>1.</B></KBD><KBD style=margin-left:36pt></KBD><B>Summary</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>BioHarvest Sciences Inc. (the &#8220;Company&#8221; or &#8220;BioHarvest Sciences&#8221;) was incorporated under the Business Corporations Act of British Columbia on April 19, 2013.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>On February 14, 2025, the Company completed a voluntary delisting process of its common shares from the Canadian Securities Exchange and continue to be listed on the Nasdaq Stock Market.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The registered address of the Company is 1140-625 Howe St., Vancouver, BC V6C 2T6, Canada.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>2.</B></KBD><KBD style=margin-left:36pt></KBD><B>Corporate Structure</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><IMG src=bhscex992_2.jpg width=549 height=284 alt='Picture 1899708423' title='Picture 1899708423'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>3.</B></KBD><KBD style=margin-left:36pt></KBD><B>Overview of the business</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company is a biotechnology company that has developed the Botanical Synthesis Platform Technology, which enables the industrial scale cultivation of active plant ingredients in bioreactors, without growing the plant itself. The platform technology is a non-genetically modified organism platform that produces plant cells with higher concentrations of active ingredients (as compared to those that are produced naturally), as well as high levels of solubility and bio-availability. The platform technology is economical, ensures consistency and avoids the negative environmental impacts associated with traditional agriculture by providing consistent product production, a year-round production cycle and products that are devoid of sugar, calories and contaminants, such as pesticides, heavy metals and residues.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>4</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><A name=_Hlk28273962 />The Company operates through two business units:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:27pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-27pt'><B>1.</B></KBD><B>The Products Business Unit</B> - Marketing and sales of science-based health and wellness nutraceutical solutions, sold as dietary supplements, functional food and beverages (capsules, powders, chews, coffee, teas and powder electrolyte beverages). The Products Business Unit sources its red grape cell powder from the CDMO Services Business Unit, it then uses other third-party manufacturers and contractors to encapsulate, integrate, package and ship the finished product for the direct sale to end consumers.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:27pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-27pt'><B>2.</B></KBD><B>The CDMO Services Business Unit</B> - A Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;) providing end-to-end development and manufacturing services for plant-based active molecules to pharmaceuticals, cosmeceuticals, nutraceuticals and nutrition customers. The CDMO serves both the Company&#8217;s Products Business Unit (as its exclusive manufacturer of VINIA&#174; red grape cell powder) and external customers from the pharmaceutical, cosmeceutical, nutraceutical and nutrition industries.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Effective January 1, 2026, following a change in the Company's organizational structure and internal management reporting lines, the Company modified the basis on which segment operating profit (loss) is measured and reviewed by the Company's chief operating decision maker. Specifically, certain revenues and operating expenses (including cost of goods, research and development, sales and marketing and general and administrative), which were previously allocated to segments based on reporting lines, are now allocated to the operating segments based on direct attribution to the relevant business unit in accordance with the revised management reporting lines, a measure of resource consumption, head-count or a revenue-based key.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The revised measurement basis reflects the adoption of an arm's length approach, whereby inter-segment revenues and the allocation of shared costs between the operating segments are determined on terms that would apply between independent parties acting at arm's length, consistent with the manner in which performance is now reviewed by the Company's chief operating decision maker.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The change did not affect the identification of the Company's reportable segments, which continue to be the Products business unit and the CDMO Services business unit, nor does it affect the Company's consolidated revenues, operating loss, net loss or financial position. The change affects only the allocation of revenues and operating expenses, and accordingly the measurement of segment operating profit (loss), among the existing segments.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Products Business Unit Activities</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Products Business Unit markets and sells VINIA&#174;, a red grape (Vitis vinifera) polyphenol/antioxidant superfruit product manufactured by the Company&#8217;s CDMO Services business unit. VINIA&#174; is a fine, dry pink-purple powder rich in piceid resveratrol and a full matrix of polyphenols in their natural state, delivering the benefits of red wine consumption without sugar, calories or alcohol. It is highly soluble and free of genetic modification or solvent extraction.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Since its U.S. launch in May 2021, the Company has achieved close to $100 million in cumulative VINIA&#174; sales. In Q1&#8217;26, VINIA&#174; revenues grew 5% year-over-year.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>5</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'>The VINIA&#174; product portfolio continues to expand through the Company&#8217;s &#8220;VINIA Inside&#8221; and &#8220;Superior Science, Superior Efficacy &amp; Superior Taste&#8221; strategies:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>VINIA&#174; capsules &#8211;&nbsp;the core product, driving the majority of revenues;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>VINIA&#174; Superfood Coffee and Tea &#8211;&nbsp;launched in late 2023, available on Amazon including K-Cup compatible formats;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>VINIA&#174; 2X Formula Chew &#8211;&nbsp;launched June 2025, targeting athletes and active consumers; 3rd-party certified by Informed Sport;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>VINIA&#174; Blood Flow Hydration Electrolyte &#8211;&nbsp;launched November 2025; rated 4.8/5&#8209;stars on Amazon within 16 weeks of launch.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;) Services Business Unit</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The CDMO Services Business Unit leverages the Botanical Synthesis Platform Technology to develop and manufacture plant-based active molecules for the Company&#8217;s Products Business Unit and for external customers. The CDMO manufactures VINIA&#174; red grape cell powder for the Products Business Unit, serving as its primary manufacturing partner, and also engages external customers under end-to-end development and manufacturing agreements.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The platform technology enables the development of patentable small molecules and/or complex molecules, with advantages including lower development costs, faster timelines and non-immunogenic properties.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Key CDMO developments and contracts:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>Tate &amp; Lyle partnership (December 2024) &#8211;&nbsp;developing next-generation plant-based sweeteners;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>Nasdaq-listed pharmaceutical company (Stage 2, May 2025) &#8211;&nbsp;advancing from cell isolation to biomass delivery for an approved drug compound;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>Fragrance compound contract (May 2025) &#8211;&nbsp;developing a plant-derived fragrance ingredient targeting the multi-billion-dollar scents market;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>Plant-derived exosomes (September 2025) &#8211;&nbsp;successful large-scale bioreactor production of exosomes enriched with viniferin, a high-value antioxidant polyphenol;&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>Saffron Tech Ltd. collaboration (October 2025) &#8211;&nbsp;developing and commercializing saffron-derived botanical compounds via parallel solid- and liquid-phase CDMO development.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company expects to sign additional contracts during 2026 with customers from the pharmaceutical, nutraceutical, cosmeceutical and food ingredients industries.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The CDMO, independently of any particular contract, also continues to invest in the development of additional molecules and compounds in order to advance their cell culture state before offering them to customers. One of the examples is the Olive Cell compound, which not only has reached a stage 3 synthesis developmental stage, but has also demonstrated in-vitro results for reducing fat accumulation in human liver cells (NAFLD model). Other examples include Pomegranate and blueberry.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>6</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Environmental, Social and Governance Reporting</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company published its inaugural ESG Report in September 2021, aligned with the UN Sustainable Development Goals, TCFD and SASB frameworks, and received the Business Intelligence Group&#8217;s Sustainability Leadership Award in 2022. The Company has adopted the COSO Internal Control &#8211;&nbsp;Integrated Framework (2013) and has implemented key HR policies including Belonging, Inclusion, Diversity and Equity; Whistle Blower; and Grievance policies, which were rolled out to all employees in Q2&#160;2025.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Significant Developments</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>To better understand the Company&#8217;s financial results, it is important to gain an appreciation of the significant events, transactions and activities that occurred during or have affected the period under review up to and including the date of this MD&amp;A.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>During the three months period ended March 31, 2026, the Company fully repaid its short-term 16% and 20% loan facilities.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>On April 29, 2026, the Company announced a strategic leadership transition directly aligned with the evolution of its &#8220;two-lens&#8221; growth strategy. Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumed the role of Chief Executive Officer, consolidating leadership of R&amp;D, Manufacturing, and Operations under the CDMO Services Business Unit in a unified structure. Ilan Sobel, who served as Chief Executive Officer since 2020, transitioned from his executive role and was appointed to the Company&#8217;s Board of Directors, where he will maintain a focused mandate on the Products business and the continued expansion of VINIA&#174;. The transition reflects the Board&#8217;s conviction that dedicated, segment-aligned leadership will strengthen the Company&#8217;s long-term competitive position, and is consistent with the change in organizational structure and internal management reporting lines implemented effective January 1, 2026, under which inter-segment revenues and cost allocations were restructured on an arm&#8217;s length basis to better reflect the distinct operations of each business unit.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Selected Quarterly Information</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%><TR><TD valign=middle bgcolor=#DBE5F1 style=width:159.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=3 valign=middle bgcolor=#DBE5F1 style=width:202.75pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>Three month period ended March 31,</B></P>
</TD></TR>
<TR><TD valign=middle bgcolor=#DBE5F1 style=width:159.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:67.05pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2026</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:67.05pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2025</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:68.65pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2024</B></P>
</TD></TR>
<TR><TD valign=middle style=width:159.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=3 valign=middle style='width:202.75pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>USD in thousands</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:159.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>Revenues</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:67.05pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>8,507</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:67.05pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>7,860</FONT></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:68.65pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>5,344</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:159.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>Net loss and comprehensive loss</P>
</TD><TD valign=middle style=width:67.05pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>(2,641)</B></P>
</TD><TD valign=bottom style=width:67.05pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>(2,338)</FONT></P>
</TD><TD valign=bottom style=width:68.65pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>(6,581)</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:159.9pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Basic and diluted loss per share </P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:67.05pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>(0.11)</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:67.05pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>(0.13)</FONT></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:68.65pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(0.48)</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%><TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:189pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=3 valign=middle bgcolor=#DBE5F1 style=width:238.7pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>As at March 31,</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:189pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:76.5pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2026</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:81pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2025</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:81.2pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>2024</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:189pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=3 valign=middle style='width:238.7pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.5pt solid #000000;border-bottom:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>USD in thousands</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:189pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>Cash and cash equivalents</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:76.5pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>19,167</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:81pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,401</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:81.2pt;padding-left:1.4pt;padding-right:1.4pt;border-top:0.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,436</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:189pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>Total Assets</P>
</TD><TD valign=middle style=width:76.5pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>45,558</B></P>
</TD><TD valign=bottom style=width:81pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>26,591</FONT></P>
</TD><TD valign=bottom style=width:81.2pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>12,913</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:189pt;padding-left:1.4pt;padding-right:1.4pt><P style='font:11pt Times New Roman;margin:0'>Total current liabilities</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:76.5pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><B>9,578</B></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:81pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>18,933</FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:81.2pt;padding-left:1.4pt;padding-right:1.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>13,316</FONT></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:189pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Total non-current liabilities</P>
</TD><TD valign=middle style='width:76.5pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>12,957</B></P>
</TD><TD valign=top style='width:81pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>8,534</FONT></P>
</TD><TD valign=top style='width:81.2pt;padding-left:1.4pt;padding-right:1.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>2,781</FONT></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>7</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Three-month period ended March 31, 2026, compared to the three-month period ended March 31, 2025:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Revenues were $8,507 thousands for the three months ended March 31, 2026, of which 95% relates to the Products Business Unit of the Company, as compared to $7,860 thousands during the same period in the prior year. In Q1&#8217;26, the Products Business Unit grew 5% and the CDMO services Business Unit grew 135% as compared to the same period in the prior year.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Cost of revenues were $3,470 thousands for the three months ended March 31, 2026, as compared to $3,265 thousands during the same period in the prior year. The increase is due to revenue mix, growth in production, demand and sales during the period.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Gross margins were 59% for the three months ended March 31, 2026, as compared to 58% during the same period in the prior year.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Research and development expenses were $1,394 thousands for the three months ended March 31, 2026, as compared to $1,245 thousands during the same period in the prior year. The change is mainly due to an increase in wages and salaries (related to the CDMO Services Business Unit) and professional fees.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Sales and marketing expenses, which relate mainly to the Products Business Unit were $4,126 thousands for the three months ended March 31, 2026, as compared to $3,681 thousands during the same period in the prior year. The change is due to the higher marketing expenditure and wages and salaries required to support sales growth in both segments.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>General and administrative expenses were $1,351 thousands for the three months ended March 31, 2026, as compared to $1,388 thousands during the same period in the prior year.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Finance expenses, net were $761 thousands for the three months ended March 31, 2026, as compared to $581 thousands during the same period in the prior year. The net finance expenses reported do not reflect a cash outflow burden but are primarily attributable to non-cash items - most notably the accretion of interest on accounting provisions recognized under IFRS. These non-cash charges have no impact on the Company's liquidity or cash position.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>On March 31, 2026, the Company had cash and cash equivalents of $19,167 thousands (March 31, 2025, $3,401 thousands).</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>8</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Summary of Quarterly Results</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The following represents the summarized quarterly financial results for the past eight quarters:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:103.76%><TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:2.9pt'>&nbsp;</P>
</TD><TD colspan=4 valign=middle bgcolor=#DBE5F1 style=width:302pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>Three-month period ended</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:2.9pt'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:70.85pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>March 31,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>2026</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:82.6pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>December 31,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>2025</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:89.75pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'><B>September 30,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'><B>2025</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:58.8pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>June 30,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-left:5.65pt;margin-right:2.9pt'>&nbsp;</P>
</TD><TD colspan=4 valign=middle style='width:302pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'><B>USD in thousands</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>Revenues</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:70.85pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>8,507</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style='width:82.6pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>9,066</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:89.75pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>9,067</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:58.8pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>8,515</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'><A name=_Hlk80700915 />Net loss before income taxes</P>
</TD><TD valign=middle style=width:70.85pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,595</P>
</TD><TD valign=middle style=width:82.6pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,268</P>
</TD><TD valign=top style=width:89.75pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,450</P>
</TD><TD valign=top style=width:58.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>4,041</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>Net loss</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:70.85pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,641</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:82.6pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,204</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:89.75pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,513</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:58.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>4,080</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:146.25pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>Net loss per share </P>
</TD><TD valign=middle style='width:70.85pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>(0.11)</P>
</TD><TD valign=middle style='width:82.6pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>(0.10)</P>
</TD><TD valign=top style='width:89.75pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>(0.14)</P>
</TD><TD valign=top style=width:58.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>(0.24)</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:146.25pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt;margin-right:2.85pt'>&nbsp;</P>
</TD><TD colspan=4 valign=middle style='width:302pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.85pt'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>&nbsp;</P>
</TD><TD colspan=4 valign=middle bgcolor=#DBE5F1 style='width:302pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'><B>Three-month period ended</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:70.85pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>March 31,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'><B>2025</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:82.6pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>December 31,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'><B>2024</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:89.75pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'><B>September 30,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'><B>2024</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:58.8pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-9.1pt;margin-left:9.1pt;margin-right:2.9pt'><B>June 30,</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'><B>2024</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>&nbsp;</P>
</TD><TD colspan=4 valign=middle style='width:302pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'><B>USD in thousands</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>Revenues</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:70.85pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>7,860</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:82.6pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>7,278</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:89.75pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>6,539</P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:58.8pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>6,027</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.85pt'>Net loss before income taxes</P>
</TD><TD valign=top style=width:70.85pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,300</P>
</TD><TD valign=top style=width:82.6pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,948</P>
</TD><TD valign=top style=width:89.75pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,689</P>
</TD><TD valign=top style=width:58.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>687</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:146.25pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>Net loss</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:70.85pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,338</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:82.6pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,956</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:89.75pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>2,689</P>
</TD><TD valign=top bgcolor=#DBE5F1 style=width:58.8pt;padding-left:5.4pt;padding-right:5.4pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>687</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:146.25pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>Net loss per share </P>
</TD><TD valign=top style='width:70.85pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>(0.13)</P>
</TD><TD valign=top style='width:82.6pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>(0.17)</P>
</TD><TD valign=top style='width:89.75pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:2.9pt'>(0.16)</P>
</TD><TD valign=top style='width:58.8pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-1.6pt'>(0.04)</P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Financial instruments and risk management</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company is exposed to a variety of financial risks, which results from its financing, operating and investing activities. The objective of financial risk management is to contain, where appropriate, exposures to these financial risks to limit any negative impact on the Company's financial performance and position. The Company's financial instruments are its Cash and cash equivalents, Bank deposits, Restricted cash, Trade accounts receivable, Other accounts receivable, Trade accounts payable, Other accounts payable and Liability to Agricultural Research Organization. The main purpose of these financial instruments is to raise finance for the Company's operation. The Company actively measures, monitors and manages its financial risk exposures by various functions, including the segregation of duties and the application of financial control principals. The risks arising from the Company's financial instruments are mainly currency risk and liquidity risk. The Company has no interest rate risk as the balances exposure to interest is minimal. The risk management policies employed by the Company to manage these risks are discussed below.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Foreign currency risk</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Foreign exchange risk arises when the Company enters into transactions denominated in a currency other than its functional currency. The Company is exposed to currency risk to the extent that there is a mismatch between the currency in which it is denominated and the respective functional currency of the company. The currencies in which some transactions are primarily denominated are CAD, US dollars and NIS. The Company's policy is not to enter into any economic hedging transactions to neutralize the effects of foreign currency fluctuations. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>9</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Liquidity and Capital resources</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The consolidated financial statements have been prepared on a going concern basis whereby the Company is assumed to be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern assumption was not appropriate for the consolidated financial statements, then adjustments of a material nature would be necessary in the carrying value of assets such as property and equipment, liabilities, the reported expenses, and the balance sheet classifications used. Management continues to pursue financing opportunities for the Company to ensure that it will have sufficient cash to carry out its planned programs beyond the next year.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>At March 31, 2026, the Company had cash and cash equivalents of $19,167 thousands (March 31, 2025, $3,401 thousands). The Company had current assets of $28,320 thousands (March 31, 2025, $9,643 thousands) and current liabilities of $9,578 thousands (March 31, 2025, $18,933 thousands).</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>At March 31, 2026, the Company had net working capital of $18,742 thousands (March 31, 2025, negative $9,290 thousands).</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>During the three months ended March 31, 2026, the Company&#8217;s overall position of cash and cash equivalents decreased by $3,812 thousands (March 31, 2025, increase by $1,015 thousands). This change in cash and cash equivalents can be attributed to the following:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>The Company&#8217;s net cash used in operating activities during the three months ended March 31, 2026, was $1,379 thousands as compared to net cash used of $1,427 thousands for the three months ended March 31, 2025. This amount is primarily a result of the losses incurred in the operations of the Company.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>The Company&#8217;s net cash used in investing activities during the three months ended March 31, 2026 was $1,593 thousands as compared to net cash used of $680 thousands for the three months ended March 31, 2025. The increase is primarily attributable to the placement of short-term bank deposits and capital expenditures for property and equipment, both of which are aligned with the Company's ongoing growth strategy and long-term operational infrastructure investments&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Symbol;margin-left:-18pt'>&#183;</KBD>The Company&#8217;s net cash used in financing activities during the three months ended March 31, 2026, was $840 thousands as compared to net cash provided by financing activities of $3,122 thousands for the three months ended March 31, 2025.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company has incurred operating losses since inception and has not yet achieved sustained positive cash flows from operations. Management believes that existing cash and cash equivalents, together with expected cash flows from operations, will be sufficient to fund core operating requirements for at least the next twelve months, assuming the deferral of certain non-essential capital expenditures and the execution of management&#8217;s operating plan. However, the Company&#8217;s ability to continue as a going concern remains dependent on the successful execution of its plan and, if necessary, access to additional capital. Therefore, the Company has substantial doubts about the Company's ability to continue as a going concern.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company may seek to raise additional capital to support its long-term growth strategy, including through the issuance of equity or equity-linked securities, debt financing, or other strategic financing arrangements. The Company&#8217;s ability to raise additional capital, if and when needed, will depend on, among other things, market conditions, investor demand, and the </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>10</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'>Company&#8217;s operating performance. There can be no assurance that such financing will be available on favorable terms, or at all.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Off Balance Sheet Agreements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company has not entered into any material off-balance sheet arrangements such as guarantee contracts, contingent interests in assets transferred to unconsolidated entities, derivative financial obligations or arrangements with respect to any obligations under a variable interest equity arrangement.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Transactions with Related Parties</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company's key management personnel have the authority and responsibility for overseeing, planning, directing, and controlling the activities of the Company. Key management personnel include members of the Board of Directors, the Chief Executive Officer and the Chief Financial Officer.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The compensation earned by key management for the three months period ended March 31, 2026, and 2025, was as follows:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Related party transactions:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:14.2pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%><TR style=height:14.15pt><TD valign=middle bgcolor=#DBE5F1 style='width:315.8pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>For the year ended December,</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:54.9pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>For the three months ended March 31, 2026</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:57pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>For the three months ended March 31, 2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:315.8pt;padding-left:2.8pt;padding-right:2.8pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><B>Compensation for key management personnel of the Company:</B></P>
</TD><TD valign=middle style='width:54.9pt;padding-left:2.8pt;padding-right:2.8pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:57pt;padding-left:2.8pt;padding-right:2.8pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style=width:315.8pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0'>Management fees</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:54.9pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>475</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:57pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'>455</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style=width:315.8pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0'>Share based payments</P>
</TD><TD valign=middle style=width:54.9pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>50</B></P>
</TD><TD valign=middle style=width:57pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>7</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Related party balances:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:99%><TR style=height:11.9pt><TD valign=middle bgcolor=#DBE5F1 style='width:315pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:54pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>As of</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'><B>March 31, 2026</B></P>
</TD><TD valign=bottom bgcolor=#DBE5F1 style='width:58.7pt;padding-left:2.8pt;padding-right:2.8pt;border-bottom:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>As of</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'><B>December 31, 2025</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=middle style='width:315pt;padding-left:2.8pt;padding-right:2.8pt;border-top:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0;margin-left:4.4pt'><B>Due to key management personnel of the Company:</B></P>
</TD><TD valign=middle style='width:54pt;padding-left:2.8pt;padding-right:2.8pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style='width:58.7pt;padding-left:2.8pt;padding-right:2.8pt;border-top:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style=width:315pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0;margin-left:4.4pt'>Management fees</P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:54pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>337</B></P>
</TD><TD valign=middle bgcolor=#DBE5F1 style=width:58.7pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>227</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:315pt;padding-left:2.8pt;padding-right:2.8pt><P style='font:11pt Times New Roman;margin:0;margin-left:4.4pt'>Prepaid expenses</P>
</TD><TD valign=middle style=width:54pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>(26)</B></P>
</TD><TD valign=middle style=width:58.7pt;padding-left:2.8pt;padding-right:2.8pt><P align=center style='font:11pt Times New Roman;margin:0'><B>(26)</B></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Critical Accounting Estimates and Judgements</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>11</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'>The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>a.</B></KBD><KBD style=margin-left:36pt></KBD><B>Liability for Agricultural Research Organization:</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Each reporting period, the Company measures the Liability to Agricultural Research Organization, based on discounted cash flows derived from Company's future anticipated revenues.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'><B>b.</B></KBD><KBD style=margin-left:36pt></KBD><B>Incremental borrowing rate:</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company measures lease liabilities at the present value of future lease payments, discounted using the incremental borrowing rate (&#8220;IBR&#8221;) when the interest rate implicit in the lease cannot be readily determined. Determining the IBR requires judgment and involves estimating reference interest rates, credit risk adjustments, lease term assumptions and economic environment factors.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Common Share Data</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>As at the date of this MD&amp;A, the Company had the following securities issued and outstanding:</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR style=height:11.9pt><TD valign=top style='width:107.85pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Common shares</B></P>
</TD><TD valign=top style='width:107.85pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Stock options</B></P>
</TD><TD valign=top style='width:107.9pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>Warrants</B></P>
</TD><TD valign=top style='width:107.9pt;padding-left:5.4pt;padding-right:5.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><B>RSUs</B></P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top bgcolor=#DBE5F1 style='width:107.85pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>22,667,842</FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:107.85pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>2,583,781</FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:107.9pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>610,742</FONT></P>
</TD><TD valign=top bgcolor=#DBE5F1 style='width:107.9pt;padding-left:5.4pt;padding-right:5.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-family:Calibri>268,230</FONT></P>
</TD></TR>
</TABLE>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Investor Relations Contracts</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>LifeSci Advisors, LLC</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Pursuant to the investor relations agreement dated February 16, 2026 (the &#8220;LifeSci Agreement&#8221;) between the Company and LifeSci Advisors, LLC (hereafter &#8220;LifeSci &#8221;), LifeSci provides investor relations services to the Company. In consideration of LifeSci&#8217;s services, LifeSci is entitled to receive a monthly cash fee of $12,500 for the first 3 months following the effective date of the agreement. Following that, the monthly cash fees will be increased to $15,000.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Contractual Obligations</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company has no contractual obligations that have not been disclosed.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>12</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Risks and Uncertainties</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Global Economic Uncertainty</B>. The Company&#8217;s ability to raise capital is subject to the risk of adverse changes in the market value of the Company&#8217;s share price. Periods of macroeconomic weakness or recession and heightened market volatility caused by adverse geopolitical developments could increase these risks, potentially resulting in adverse impacts on the Company&#8217;s ability to raise further capital on favorable terms. The impact of geopolitical tension, such as the conflict in the Middle East, a deterioration in the bilateral relationship between the US and China or an escalation in conflict between Russia and Ukraine, including any resulting sanctions, export controls or other restrictive actions that may be imposed by the US and/or other countries against governmental or other entities in, for example, Russia, also could lead to disruption, instability and volatility in global trade patterns, which may in turn impact the Company&#8217;s ability to source necessary raw materials and other inputs for manufacturing or the Company&#8217;s ability to close new revenue generating orders.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Geographical Risks</B>. The Company&#8217;s principal place of business, operations and its facilities, where most of its employees are employed, are located in Rehovot and Yavne, Israel. In addition, the majority of the Company&#8217;s key employees and senior management are Israeli citizens. Accordingly, political, economic, and military conditions in Israel may directly affect the Company&#8217;s business.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>On October 7, 2023, Hamas militants infiltrated Israel&#8217;s southern border from the Gaza Strip and carried out attacks against civilian and military targets in Israel. Following these events, the Government of Israel declared war against Hamas and the Israel Defense Forces initiated a large-scale mobilization of military reservists. Hostilities between Israel and Hamas continued through 2023, 2024 and 2025. On October 9, 2025, the Israeli Cabinet approved a ceasefire and hostage exchange agreement between Israel and Hamas that was brokered by the United States and took effect on October 10, 2025.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>During this period, hostilities also escalated along Israel&#8217;s northern border involving Hezbollah forces operating from Lebanon. On November 27, 2024, Israel and Lebanon agreed to a ceasefire arrangement that remained in effect until February 18, 2025.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>In June 2025, tensions between Israel and Iran escalated significantly and resulted in military operations between the two countries. On June 24, 2025, Israel and Iran agreed to an immediate ceasefire.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>On February 28, 2026, the United States and Israel conducted coordinated aerial operations targeting military and governmental facilities in Iran. Subsequently, Iran launched missile attacks across parts of the Middle East and Hezbollah launched barrages of rockets toward northern Israel, leading to retaliatory actions by Israel.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>On April 5, 2026, a ceasefire agreement was reached between Israel, the United States and Iran, which took effect immediately. As of the date of this MD&amp;A, the ceasefire remains in place and the immediate hostilities have subsided.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Notwithstanding the ceasefire, the regional security situation continues to create uncertainty and could adversely affect Israel's economy, the Company's operations, employees, business partners, supply chain and overall business environment. The Company confirms that it has a business continuity plan and procedures in place, ensuring operational and financial continuity. As of the </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>13</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'>date of this MD&amp;A, the Company has not experienced a material adverse impact on its operations; however, the Company continues to monitor the situation closely and cannot predict the ultimate impact that these developments may have on its business, financial condition or results of operations.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Market Risks</B>. The Company&#8217;s securities trade on public markets and the trading value thereof is determined by the evaluations, perceptions and sentiments of both individual investors and the investment community taken as a whole. Such evaluations, perceptions and sentiments are subject to change, both in short-term time horizons and long-term time horizons. An adverse change in investor evaluations, perceptions and sentiments could have a material adverse outcome on the Company and its securities.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Financing Risks</B>. The Company will be dependent on raising capital through a combination of debt and/or equity offerings. There can be no assurance that the capital markets will remain favorable in the future, and/or that the Company will be able to raise the financing needed to continue its business at favorable terms, or at all. Restrictions on the Company&#8217;s ability to finance could have a material adverse outcome on the Company and its securities.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Share Price Volatility and Price Fluctuations</B>. In recent years, the securities markets all over the world have experienced a high level of price and volume volatility, and the market prices of securities of many corporations have experienced wide fluctuations which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Key Personnel Risks</B>. The Company&#8217;s efforts are dependent to a large degree on the skills and experience of certain of its key personnel, including the board of directors. The Company does not maintain &#8220;key man&#8221; insurance policies on these individuals. Should the availability of these persons&#8217; skills and experience be in any way reduced or curtailed, this could have a material adverse outcome on the Company and its securities.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>General Business Risk and Liability</B>. Given the nature of the Company's business, it may from time to time be subject to claims or complaints from investors or others in the normal course of business. The legal risk facing the Company, its directors, officers and employees in this respect includes potential liability for violations of securities laws, breach of fiduciary duty or misuse of investors' funds. Some violations of securities laws and breach of fiduciary duty could result in civil liability, fines, sanctions or the suspension or revocation of the Company's right to carry on its existing business. The Company may incur significant costs in connection with such potential liabilities.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Competition</B>. There is the potential that the Company will face intense competition from other companies, some of which can be expected to have more financial resources, industry, manufacturing and marketing experience than the Company. Additionally, there is potential that the industry will undergo consolidation, creating larger companies that may have increased geographic scope and other economies of scale. Increased competition between larger, better-financed competitors with geographic or other structural advantages could materially and adversely affect the business, financial condition and results of operations of the Company. To remain competitive, the Company will require a continued level of investment in research and development, marketing, sales and client support. The Company may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Company.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>14</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<TABLE align=center style=border-collapse:collapse;width:100%><TR style=height:25.3pt><TD valign=top style='width:431.5pt;border-bottom:1.5pt solid #000000'><P align=justify style='font:12pt Times New Roman;margin:0'><B>BIOHARVEST SCIENCES INC.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>Management&#8217;s Discussion and Analysis</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin:0'><B>Reliance on Key Business Inputs</B>. The Company's business is dependent on a number of key inputs and their related costs including raw materials and suppliers related to its growing operations as well as electricity, water, and other utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company. Any liability to secure required supplies and services or to do so on appropriate terms could also have a materially adverse impact on the business, financial condition, and operating results of the Company.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Potential product recalls</B>. Manufacturers and distributers of products are sometimes subjected to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packing safety and inadequate or inaccurate labeling disclosers. If the Company's product is recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expenses of the recall and any legal proceedings that might arise in connection with the recall.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>The Company may lose a significant number of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Although the Company had detailed procedures in place for testing finished products, there can be no assurance that any quality, potency or contamination problem will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuit. Additionally, if one of the Company's products was subject to recall, the image of the Company could be harmed. A recall for any one of the foregoing reasons could lead to decreased demand for the Company's products and could have a material adverse effect on the results of operations and financial condition of the Company.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>History of Net Losses; Accumulated Deficit; Lack of Revenue from Operations</B>. The Company has incurred net losses to date. The Company may continue to incur losses. There is no certainty that the Company will operate profitably or provide a return on investment in the future.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Uninsurable risks</B>. The Company may become subject to liability for events against which it cannot insure or against which it may elect not to insure. Such events could result in substantial damage to property and personal injury. The payment of any such liabilities may have a material, adverse effect on the Company's financial position.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>No History of Dividends</B>. Since incorporation, the Company has not paid any cash or other dividends on its common stock and does not expect to pay such dividends in the foreseeable future, as all available funds will be invested primarily to finance the Company&#8217;s operations. The Company will need to achieve profitability prior to any dividends being declared.</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'><B>Other Information</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>Additional information related to the Company is available for viewing on SEDAR+ at www.sedarplus.ca. This additional information is not incorporated into this Management's Discussion and Analysis and does not constitute a part of this Management's Discussion and Analysis.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:9pt Times New Roman;margin:0'>15</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>bhsc_ex993.htm
<DESCRIPTION>CERTIFICATION OF CEO
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2026 [PPXC4Y912124VAJXLJL1]. www.edgarsuite.com -->
<HEAD>
<TITLE>Certificate CEO</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:54pt;width:504pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=middle style=width:503.5pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:5.15pt'>This is an unofficial consolidation of Form 52-109F2 <I>Certification of Interim Filings Full Certificate </I>reflecting amendments made effective January 1, 2011 in connection with Canada&#8217;s changeover to IFRS. The amendments apply for financial periods relating to financial years beginning <B><I>on or after </I></B>January 1, 2011. This document is for reference purposes only and is not an official statement of the law.</P>
</TD></TR>
</TABLE>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:173.4pt;margin-right:173.3pt'><B>Form 52-109F2</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:173.4pt;margin-right:173.3pt'><B><I>Certification of Interim Filings Full Certificate</I></B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:173.4pt;margin-right:173.3pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>I, <B>Zaki Rakib, the Chief Executive Officer of BioHarvest Sciences Inc.</B>, certify the following:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:23.4pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>1.</KBD><B><I>Review: </I></B>I have reviewed the interim financial report and interim MD&amp;A (together, the &#8220;interim filings&#8221;) of <B>BioHarvest Sciences Inc. </B>(the &#8220;issuer&#8221;) for the interim period ended <B>March 31, 2026</B>.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:54pt;margin-right:23.4pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:20.75pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>2.</KBD><B><I>No misrepresentations: </I></B>Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:54pt;margin-right:20.75pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:22.65pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>3.</KBD><B><I>Fair presentation: </I></B>Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:27pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>4.</KBD><B><I>Responsibility: </I></B>The issuer&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&amp;P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 <I>Certification of Disclosure in Issuers&#8217; Annual and Interim Filings, </I>for the issuer.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:24.35pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.</KBD><B><I>Design: </I></B>Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:54pt;margin-right:24.35pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:90pt;margin-right:19.95pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>(a)</KBD>designed DC&amp;P, or caused it to be designed under our supervision, to provide reasonable assurance that&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:90pt;margin-right:19.95pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:126pt;margin-right:19.25pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>(i)</KBD>material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:126pt;margin-right:19.25pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:126pt;margin-right:25.45pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>(ii)</KBD>information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:90pt;margin-right:25.1pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36.6pt'>(b)</KBD>designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36.6pt;margin-left:90pt;margin-right:25.1pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:11pt Times New Roman;margin:0'>1</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:20.95pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.1</KBD><B><I>Control framework: </I></B>The control framework the issuer&#8217;s other certifying officer(s) and I used to design the issuer&#8217;s ICFR is the Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.2</KBD><B><I>ICFR &#8211; material weakness relating to design: </I>N/A</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.3</KBD><B><I>Limitation on scope of design: </I>N/A</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:21.15pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>6.</KBD><B><I>Reporting changes in ICFR: </I></B>The issuer has disclosed in its interim MD&amp;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on <B>January 1, 2026</B>, and ended on <B>March 31, 2026, </B>that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>Date: <B>May 14, 2026</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:28.35pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'><FONT style='border-bottom:1px solid #000000'><I>/s/ </I><I>Zaki Rakib</I></FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>Zaki Rakib</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>Chief Executive Officer</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:16.7pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:11pt Times New Roman;margin:0'>2</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>bhsc_ex994.htm
<DESCRIPTION>CERTIFICATION OF CFO
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2026 [PPXC4Y912124VAJXLJL1]. www.edgarsuite.com -->
<HEAD>
<TITLE>Certificate CFO</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:54pt;width:504pt><P style='font:10pt Times New Roman;margin:0;margin-left:12.35pt'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=middle style=width:503.5pt;padding-left:5.4pt;padding-right:5.4pt><P align=justify style='font:11pt Times New Roman;margin-top:5.95pt;margin-bottom:6pt;margin-left:5.15pt'>This is an unofficial consolidation of Form 52-109F2 <I>Certification of Interim Filings Full Certificate </I>reflecting amendments made effective January 1, 2011 in connection with Canada&#8217;s changeover to IFRS. The amendments apply for financial periods relating to financial years beginning <B><I>on or after </I></B>January 1, 2011. This document is for reference purposes only and is not an official statement of the law.</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0;margin-left:12.35pt'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:173.4pt;margin-right:173.3pt'><B>Form 52-109F2</B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:173.4pt;margin-right:173.3pt'><B><I>Certification of Interim Filings Full Certificate</I></B></P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-left:173.4pt;margin-right:173.3pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>I, <B>Bar Dichter, the Chief Financial Officer of BioHarvest Sciences Inc.</B>, certify the following:</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:23.4pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>1.</KBD><B><I>Review: </I></B>I have reviewed the interim financial report and interim MD&amp;A (together, the &#8220;interim filings&#8221;) of <B>BioHarvest Sciences Inc. </B>(the &#8220;issuer&#8221;) for the interim period ended <B>March 31, 2026</B>.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:54pt;margin-right:23.4pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:20.75pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>2.</KBD><B><I>No misrepresentations: </I></B>Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:54pt;margin-right:20.75pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:22.65pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>3.</KBD><B><I>Fair presentation: </I></B>Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:27pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>4.</KBD><B><I>Responsibility: </I></B>The issuer&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&amp;P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 <I>Certification of Disclosure in Issuers&#8217; Annual and Interim Filings, </I>for the issuer.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:24.35pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.</KBD><B><I>Design: </I></B>Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:54pt;margin-right:24.35pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:90pt;margin-right:19.95pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>(a)</KBD>designed DC&amp;P, or caused it to be designed under our supervision, to provide reasonable assurance that&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:90pt;margin-right:19.95pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:126pt;margin-right:19.25pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>(i)</KBD>material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36pt;margin-left:126pt;margin-right:19.25pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:126pt;margin-right:25.45pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>(ii)</KBD>information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:90pt;margin-right:25.1pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36.6pt'>(b)</KBD>designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;text-indent:-36.6pt;margin-left:90pt;margin-right:25.1pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:11pt Times New Roman;margin:0'>1</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:20.95pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.1</KBD><B><I>Control framework: </I></B>The control framework the issuer&#8217;s other certifying officer(s) and I used to design the issuer&#8217;s ICFR is the Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.2</KBD><B><I>ICFR &#8211; material weakness relating to design: </I>N/A</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>5.3</KBD><B><I>Limitation on scope of design: </I>N/A</B>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:21.15pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-36pt'>6.</KBD><B><I>Reporting changes in ICFR: </I></B>The issuer has disclosed in its interim MD&amp;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on <B>January 1, 2026</B>, and ended on <B>March 31, 2026, </B>that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:54pt;margin-right:21.15pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>Date: <B>May 14, 2026</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'><FONT style='border-bottom:1px solid #000000'><I>/s/ </I><I>Bar Dichter</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>Bar Dichter</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>Chief Financial Officer</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:18pt'> &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=right style='font:11pt Times New Roman;margin:0'>2</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>bhscex991_1.jpg
<TEXT>
begin 644 bhscex991_1.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 60# 2(  A$! Q$!_\0
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ME3&Y$9AGU J:JVH_\@RZ_P"N3?R-)[$5':#:.$C\;:S+PD$#D#)VQL?ZT_\
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MWG>Y6(B="RX()[$<\5H_#GQ'>^+/!%EK&H)"MS.7#"%2J\,0, D^E<;^T/\
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M9%6O&H*_"/5@W4:8<_\ ?-9%M'<^+O$7GR(5MU(W^B(.BY]370?$8 ?#;Q
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M6_%O_G_G_P#!L?\ &M?X)^.O#/A;PM?6FM:I':3R79D1&1CE=H&> ?2O3?\
MA</@'_H88?\ OU)_\33&CF/A/X-\<>'/$EY=>)[F66TDM#'&'O3,-^]3TSQP
M#S7K=U:P7MK+:W4*302J4DC<95E/4$5S>B_$;PGXBU2/3=)UB.YO) S+&L;C
M( R>2 .E9/Q9\8ZWX+\-1WNCV"3&63RY+E_F6W]"5[YZ>E(9R?B#]G72;VX>
M;1-4ET\,<^1*GFHOT.01^9KD;GX*_$'PZK76BZHD[)SBSNGBD('L< _3->I>
M"OC%X<\2Z="FHWL.FZHJ@2PW#;%9O5&/!!].M=7J7C'PWI%L;B^URPBC )'[
M]23] #D_A0(\>^&'Q:UL^)8O"WBTM))+(8(YY4VRQ2]D?USTSUS7OM?*%M=C
MQ]\>H;_2;=A!+?),"5P1'&!EV';(7/XBOJ^@:.*^+?\ R2KQ!_UP7_T-:X+]
MFS_D#:]_U\Q_^@FN]^+?_)*O$'_7!?\ T-:X+]FS_D#:]_U\Q_\ H)H ]RHH
MHH **** "HYXA/;R0DD!U*DCWJ2D)P"0,^U FDU9G)CP#8X_X^[C\A1_P@-C
M_P _=Q^0I]IJ=_?[G75K2WN Y'V.2(<8.,$DYS]*U-2OKM+FVT^R$?VN=2S2
M.,K&HZG'>N=0IM7L>'#"Y?*#FJ6FGSOZ/\[%6Q\':792K*RO.ZG(\TY _"M]
ME#(5Z C%9]E#JD-P1=W<-S 5X(BV,#^'&*S#K%Y_PB4VH;T%PLA4-MX \S;T
M^E:+EBM%8[:<J&%@U&'+HW;3I\_/N3Z/X7MM&O&N8IY9&*%</C%;M8=E+?/>
M1K)K5C.F?FCC0;F'MS4=OKTB:_=V5V +?S1'#+C #;0=I^N>*(N,59:"H5</
MAX1C&/*F[=-]^C9)J'A32]0D,K1-#(>K1'&?J.E9_P#P@5A_S]7'Z?X5IQZN
M\46KSW/S1V<I5 HP< =/SJ.%/$,\*W7VNUC9\,+8Q94#T+=<U+C!O8QJ4,%5
ME?V7,WV7G:[U7^90_P"$!L/^?JX_3_"I(? NF1N&DEN)0/X2P /Y"K.JZA>Q
M:Q!9PWEO:H\!D9Y5!&0<8Y-2QW=Y;Z5>W+7=OJ$L2ED$"@ $#H<$TN2G?8A8
M7 *;2I?#^BOM>_X&G:V=O90"&VA2*,=%455UW2(M?T&]TF>1XXKN(Q.Z?> /
M<9K.TR[O+MX)4UJSN V#+!Y84@=\<YR*Z*M8M-:'IX>K&I"\%9?+]&SC? 7P
M[T_X?Q7L=A>7-R+ME9C/MXVYZ8'O798HHJC<YGQOX*LO'6C1Z9?7,]O%',)@
MT.,Y (QR/>GZ#X1@\.>#?^$<L;VX$821%N3CS%W9Y'&,C/%='10!Y_X(^$NC
M>!M8FU2UNKJ[N9(C$K7&WY 3DD8'4X%>@8HHH ,5P'C?X2Z+XYU>'4[NZNK2
MYCB$3-;[?G .1G(/(S7?T4 8>I>&X]5\&R^'+N\G>.6V%N]SQYC 8^;TSQ69
MX#^'UA\/[6]@L+NYN5NW5V,^,@J".,#WKKZ* #%>>^,_A!H'C/5TU2:6XLKO
M;ME>VVCS<="V1U'K7H5% &?HFFRZ1H]MI\M]/?- NP7%QC>P'3=CJ<<9K0HH
MH I/IL;:O'J2NR2K&8V Z.OO]*MJB(25506Y) ZTZBDDD1&G&-VEOJ%87B_P
MQ;>,?#=QHEW/+!#.R,SQ8W#:P8=?I6[13+/&/^&</#O_ $&=3_\ '/\ "C_A
MG#P[_P!!G4__ !S_  KV>B@+'FOA#X,Z/X-\20:U9ZE>SS0JZA)=NT[E(/0>
M]>B75I;WUI+:W<,<]O*I22.1<JP/8BIJ* /&M=_9WT&^N7GTG4;G3@QSY+*)
M4'TR00/Q-9=O^S7;B4&Y\22-'W$=J 3^):O>:* .8\'^ = \$6SQZ3;'SI !
M+<RG=+)[$]A[# KIZ** ,GQ+H,'B?PY>Z+<RR10W:!&>/&X<@\9^E8W@/X?V
M'@"UO+>PN[FX6Z=78SXR"!CC KKZ* "BBB@ HHHH *0YP<=>V:6B@#F+VWU&
M]MI;:YT2VEN&!5;I9%"CT;^\*M3Z9?6_V"[M66>ZM8O*D1S@2KCG!['-;M%1
MR(X_J4-6Y-MVUTTL[K9?G<SK*YU*XN3]IT]+6 +_ !2AV+?AQBLHZ3>_\(A-
M8>2#<M(S!-PP1YF[KTZ5TU%#A?<J6%4XVG)O1KIUMY>1@6,,Z7L3'PY;6HSS
M,DB$J/P&:DBT?[1)J\=Y'^YNI@\9!&>% R/0@BMNBCD0HX."24G?[NJMT2.=
MT_0[K^S-3LK^3<UPYVS \L,##?7BI8;G7H($MCIL4DJ@+]H\\!"!W(ZUNT4<
MEMF*.#C!)0DU;3IJKWUNG_F<[J]A=3:S;W:Z;%?1+ 49'=0 Q.>]6;*.\2RN
M5@TNWT^<X,8W*RN??;6S11R:W&L)%5'44GKZ=K;VO^)R]S97NI/ IT>*SG21
M7>Z$BDK@\XQR<UU%%%.,;&E'#JDV[W;]/T2"BBBJ-PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>bhscex992_1.jpg
<TEXT>
begin 644 bhscex992_1.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N C\# 2(  A$! Q$!_\0
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M)71[=&M3K04Z;NF%%%%,U"BBB@ HKB[?6?$C^.WT^2T(TX,1_JN!'CA]_O\
MUQ7:5I5I.G:[W5S&C6C53<4]';4****S-@HHHH **** "BBB@ HHHH ****
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M .YKR+[?<_\ /Y/_ -_6_P :C>5YFW22/(?5F)_G6CQ/9'H3XE7*^2GKZ_\
M %FD\Z>20+CS'+!1VR>E>NZ5"]MI-I#(,.D*JP]#BN#\(II+:@K7LA^U _N4
M<?)GUSW/UKTBJP\='(VX?P_+"5=M-R[=/4XOX@?ZK3_]Y_Y"L[P+_P AZ7_K
MW;_T):T?B!_JM/\ ]Y_Y"L[P+_R'I?\ KW;_ -"6HE_'.6O_ ,CI>J_([S4;
ML6.FW-TW_+*,M^..*\AC26\NUC!+33R 9/=B?_KUZ5XP<KX9N0%SN*@^WS#F
MN'\,*'\2V0;LY/X@&G7UFHEYY>KBZ5![:?B[?H>F6%E%IUC%:PJ D:XX[GN?
MQJS1176E8^IC%12C'9!1110,**** (YH8[B!X9D#QN-K*>A%>1:I8MINIW%F
MW(C;"D]U/(/Y5[#7G7CF-4UV-P>7A!(],$BN?$1O&Y\_Q#0C+#JKU3_!G6^%
M[TWWA^V=B2\8\IB?5>/Y8KS7]HS_ )$?3O\ L(K_ .@/7;> B?[)N5QP)LY_
M 5Q/[1G_ "(^G?\ 817_ - >M:3O!,]/+ZCJ82G.6]D>:_ /_DJ$7_7G-_2O
MJROA;0]>U3PWJ0U#2+MK6["%!(JAOE/48((KIO\ A<'C[_H8I?\ OQ'_ /$U
M9V)GV'17QY_PN#Q]_P!#%+_WXC_^)H_X7!X^_P"ABE_[\1__ !- 7+'QJ_Y*
MQK'TA_\ 12U[=\!?^26VW_7S-_Z%7R_K&LZAX@U274M4N3<WDN \I4 G P.!
MQT KZ@^ O_)+;;_KYF_]"H!'IM%%<O\ $+Q0OA#P3J&JA@+@)Y5L#WE;A?RZ
M_0&@9\[_ !N\5CQ'XZDLX'W66E VR8/#29_>-^>!_P !KTG]GSPK_9_AVZ\1
MW,6+C4&\N D<B%3U'U;/_?(KP#0-'N_%'B6RTJ!F:XO9PK.>< G+,?H,FOMS
M3=/M]*TRUT^T0);VT2Q1KZ*HP*!(^9?CSX5_L3QHNKV\>VTU93(Q X$R\./Q
MX;\378_L\>*Q<:=>^%KF3]Y;$W-J">L9/SJ/HV#_ ,"-=_\ %/PK_P );X#O
MK.)-UY;C[3:\<ET!^7\1D?C7RIX/\13^$_%FGZS#G_1Y1YJ_WHSPZ_D3^- '
MV_145M<17EK#<V[B2&9!)&Z]&4C(/Y5+0,\0_:1_Y &A?]?4G_H%<7^SU_R4
M>X_[!TG_ *''7:?M(_\ ( T+_KZD_P#0*\S^#_BG2?"'C.;4M9N'@M6LWB#+
M&SG<60@8 ST!H%U/KNBO./\ A>?@'_H*S_\ @'+_ /$T?\+S\ _]!6?_ , Y
M?_B:!G<ZTML^A:@M[C[*;:039Z;-IW?IFOA'^&O:OB3\;X_$6D3Z'X=MIX+6
MX&RXNIP%=T[JJ@G /<GMQBN ^'GA&X\9>,+/3XXV-I&XENY .$B!YY]3T'N:
M!'V%HA<Z!IQDW;_LL6[=USM&<U4\4:5_:FCN$&9X?WD?OCJ/Q%;*J%4*HP ,
M 4M*24E9F=:C&M3E3GLSQ.BMSQ5I7]F:PYC3%O/^\C] >X_/^=8=>9*+B[,_
M-Z]&5"K*E/='J_AN=KGP[92,<L(]IY]./Z5JUA>#T*^&;;/\18CZ;C6GJ.H6
M^EV3W=TQ6->.!DDGH!7I0?NIL_0\+/\ V:$Y?RK\CFO&/B6^T>ZM[6R"(SIY
MC2.N[OC K6\+ZQ+K>C+<SQA95<QN5'#$=Q^=9UOJ&@^,9A;7%H_GQ L@EX)'
M?!!_2NDM+2"QMDM[:)8H4X55[5=TUH9T%4G6=53O![(FKYM_:/\ ^1LT?_KQ
M/_H9KZ2KYM_:/_Y&S1_^O$_^AFD=K-C]FO\ X]_$?^_!_)Z]ZKX;T7Q3KOAM
M9ET;5+BQ$Y!E$+8WXSC/YFM7_A9_C?\ Z&?4/^_E )GV?17QA_PL_P ;_P#0
MSZA_W\H_X6?XW_Z&?4/^_E 7/L^JVHVOV[3+NSW;?/A>+=Z;@1G]:YKX8:C>
M:O\ #?1K_4+F2YNIHV,DLARS'>PY_ 5UU SX,O+.YTS4)[*Y1HKFVE:.13U5
ME.#_ "KZG\$?&3PWX@TVWAU.]BTW5%15ECN#L1VZ$HQXP?0G--^(_P 'K#QK
M.=3L)TT_5\8>0KF.?'3>!R#_ +0_6O!-9^%7C70W<3Z%<7$:_P#+6T'G*1Z_
M+R/Q H%L?8=M=VUY'YEK<13I_>B<,/S%35\'XU#2+C/^EV4RG_:B8''X'I71
MZ1\4/&FBLOV7Q!=R(O\ RSN6\Y<>GS9_2@+GV;17C/@+X\6FN7<.E^)+>*PN
MY"$CNHR?)=NP(/*$_4CZ5[-0,**** /G[]I7_7>&OI<_^TZSOV;_ /D:M9_Z
M\E_]#%:/[2O^N\-?2Y_]IUG?LW_\C5K/_7DO_H8H%U/I*BBB@84444 %8OBS
M_D6+SZ+_ .A"MJL7Q9_R+%Y]%_\ 0A43^%G+CO\ =:G^%_DSS[0%#>(+!6 (
M,PR".M>J_9+;_GWB_P"^!7E?A_CQ%8?]=A7K&]/[Z_G6.&^%GC<.).A._?\
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M=DD>2?![0M,\1^/X]/U>T2[M#;2N8G) W#&#P17T/_PJ+P%_T+=M_P!_)/\
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M(^:.LN[_ $"O'?VC/^1'T[_L(+_Z ]>Q4R2*.5=LD:N!SAAFM3TCY6^ 8/\
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MG\ VRSONO=./V6?)Y( ^1C]5Q^(-=Z]O!*VZ2&-VZ99033HX8H<^5$B9Z[5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%=)++:RI!+Y
M4K*0CXSM/8U+10)JZL<E;ZQKVE)]EO\ 2IKQDX6>+G</P%+8VFHZSX@@U>_M
M?LD-NN(HV/S-U_QKK**S]GW9P+ M\JG4<HIW2=NFUW:[L<[K^C7<UY#JVEL%
MOH!@J3@2#T_G53_A)-=QY7_"/R>?TS\VW/Y?UKK:*'#6Z=BIX)\[G2FX\V]K
M6?GJG9F78+J;:/(NIB,W3*V!'Z'H#VS]*I^#;.YL=",-U"\,GFL=KC!Q@5T%
M%5R:I]C58:*G"HVVXIK7K>V_W'#J=:TK7]3N;727N$N)#ACP,9/(K0M];\0R
M7,22Z$4C9P&?)^49Y-=114*FULSGA@)4](59)7;MIU=^QS7BZQNKU=.%M \O
MES[GVCH/6MO4=/@U.QDM;A<HXX/=3V(JU15\BNWW.E8:'/.3UY[77HK''^%M
M'O\ 2]<O?M4;%/*"+-_"_(QC\*MZYH]ZNI)K.D$?:T&)(CT<?_JXQ72T5*II
M1Y3"&74HT/8)NR=T^J=[Z')'Q'KS@PQZ!(L_0,V=H/KT_K6O%'J3^'9HK\(]
MXT3KB/OP<?C]*UJ*:BUN[FE+#3BVYU'+2VMOT6YPNDWGB'2-.2SCT-Y%4D[F
MR"<G-;ND:IK%Y>F*_P!*-K#L)$F3UXXK=HI1IN/4RH8&='E2JR:733_(YG4)
MM?TO59;J&,W]C(!B)>#'] /Y\YJGJ%[K'B*V.GP:1+;1R$>9+/P  <]Q7944
M.G?2^@ZF"E/FC[27++=:==TFU=(KV-J+*P@M0=PB0)GUQ5BBBM-CNC%122"B
MBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>bhscex992_2.jpg
<TEXT>
begin 644 bhscex992_2.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J D # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63XE_P"1>NO^ ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5FZ/:S6JWHF3;YET\B<@Y4XP>*TJIZ???
M;UN#Y>SR9VA^]G.,<_K424>97W%U+E%%%6,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "J>GV/V!;@>9O\Z=IONXQG''
MZ5<K-T>ZFNEO3,^[R[IXTX PHQ@<5$G'F5]Q=32HHHJQA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8WB6^N=/TV.6UD\MS,%)V@\88]_H*V:Y[QC_ ,@B+_KN
M/_06K'$-JE)H4MCG?^$FUC_G[_\ (:?X4?\ "3:Q_P _?_D-/\*R:*\/V]7^
M9_>8W9K?\)-K'_/W_P"0T_PH_P"$FUC_ )^__(:?X5DT4>WJ_P S^\+LUO\
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M?X4?\)-K'_/W_P"0T_PK)HH]O5_F?WA=FM_PDVL?\_?_ )#3_"C_ (2;6/\
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M'2N'\8_\A>+_ *X#_P!":N?'?P3IGL<]1117B&04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!K>&?^1AM?^!_^@-7H
M=>>>&?\ D8;7_@?_ * U>AU[&7_PGZ_Y&L-@K.UG2_[6LTM_.\K;('W;=W8C
M'4>M:-%=LHJ2Y9;%V.3_ .$*_P"HA_Y!_P#LJ/\ A"O^HA_Y!_\ LJZRBN?Z
ME0_E_%D\B.3_ .$*_P"HA_Y!_P#LJ/\ A"O^HA_Y!_\ LJZRBCZE0_E_%AR(
MY/\ X0K_ *B'_D'_ .RH_P"$*_ZB'_D'_P"RKK**/J5#^7\6'(CD_P#A"O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHK.URYFL]&N+BW?9*FW:V <98#O4SDHQ<GT T:*\\_X
M2;6/^?O_ ,AI_A1_PDVL?\_?_D-/\*XO[0I=G_7S(YT>AT5YY_PDVL?\_?\
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M^?O_ ,AI_A1_PDVL?\_?_D-/\*/[0I=G_7S#G1Z'17GG_"3:Q_S]_P#D-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
